# National Institute for Health and Care Excellence

Draft for consultation

# Fertility problems: assessment and treatment

[I] Tubal catheterisation

NICE guideline NGXXX

Evidence reviews underpinning recommendation 1.6.2 in the NICE guideline

September 2025

Draft for consultation

This evidence review was developed by NICE



#### **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

#### Copyright

© NICE 2025. All rights reserved. Subject to Notice of rights.

ISBN:

#### **Contents**

| Tubal cat | heteris    | sation  | 6  |
|-----------|------------|---|----|
| Revie     | w ques     | stion   | 6  |
|           | Introdu    | uction  | 6  |
|           | Summ       | ary of the protocol   | 6  |
|           | Metho      | ds and process  | 6  |
|           | Case s     | series evidence   | 7  |
|           | Summ       | ary of included studies   | 8  |
|           | Summ       | ary of the evidence   | 26 |
|           | Econo      | mic evidence  | 27 |
|           | Econo      | mic model   | 27 |
|           | The co     | ommittee's discussion and interpretation of the evidence  | 27 |
|           |            | nmendations supported by this evidence review   |    |
| Refer     | ences      | – included studies  | 29 |
| Appendic  | ces        |   | 34 |
| Appendix  | ( <b>A</b> | Review protocols  | 34 |
|           | Reviev     | w protocol for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?            | 34 |
| Appendix  | κВ         | Literature search strategies  | 40 |
|           | Literat    | ure search strategies for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction? | 40 |
| Appendix  | ( C        | Case series evidence study selection  | 48 |
|           | Study      | selection for: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?                             |    |
| Appendix  | ( D        | Evidence tables   | 49 |
|           | Evider     | nce tables for: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal   | 40 |
| Annondi   | , E        | tubal obstruction?  Forest plots  |    |
| Appendix  |            | •   | 50 |
|           | rorest     | plots for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?                 | 50 |
| Appendix  | ( F        | GRADE tables  | 59 |
|           | GRAD       | E tables for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?              | 59 |
| Appendix  | ι G        | Economic evidence study selection   | 63 |

|         | Study  | selection for: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?                           | . 63 |
|---------|--------|---|------|
| Appendi | х Н    | Economic evidence tables  | . 64 |
|         | Econo  | mic evidence tables for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction? | . 64 |
| Appendi | хI     | Economic model  | . 65 |
|         | Econo  | mic model for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?           | . 65 |
| Appendi | x J    | Excluded studies  | . 66 |
|         | Exclud | led studies for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?         | . 66 |
| Appendi | хK     | Research recommendations – full details   | . 75 |
|         | Resea  | rch recommendations for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction? | . 75 |

# 1 Tubal catheterisation

### 2 Review question

- 3 What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is
- 4 used for the treatment of proximal tubal obstruction?

#### 5 Introduction

- 6 Fallopian tubal catheterisation is a trans-cervical procedure in which a catheter is passed
- 7 through the tubal ostium into the fallopian tube. It can be done under radiological or
- 8 hysteroscopic guidance. It has been postulated to relieve proximal tubal obstruction and
- 9 hence improve the likelihood of conception over expectant management in people with this
- 10 cause of subfertility. The aim of this review is to determine the likelihood of spontaneous
- 11 conception leading to clinical pregnancy or live birth, and other outcomes, when tubal
- 12 catheterisation/cannulation is used for the treatment of proximal tubal obstruction.

#### 13 Summary of the protocol

- 14 See Table 1 for a summary of the Population, Intervention, Comparison and Outcome
- 15 (PICO) characteristics of this review.

#### 16 Table 1: Summary of the protocol (PICO table)

| abio ii Gaiiiiiai y | or the protector (1 100 table)   |
|---------------------|--|
| Population          | People undergoing tubal catheterisation/cannulation for the treatment of proximal tubal obstruction  |
| Intervention        | Tubal catheterisation/cannulation for the treatment of proximal tubal obstruction  |
| Comparison          | N/A  |
| Outcome             | Critical   |
|                     | <ul> <li>Live birth rate (spontaneous conception) as proportion of those who<br/>underwent tubal catheterisation/cannulation</li> </ul>                            |
|                     | <ul> <li>Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as<br/>proportion of those who underwent tubal catheterisation/cannulation</li> </ul> |
|                     | Important  |
|                     | <ul> <li>Ectopic pregnancy rate as proportion of those who underwent tubal catheterisation/cannulation</li> </ul>  |
|                     | <ul> <li>Miscarriage rate as proportion of those who underwent tubal catheterisation/cannulation</li> </ul>  |
|                     | <ul> <li>Tubal perforation rate as proportion of those who underwent tubal catheterisation/cannulation</li> </ul>  |

- 17 N/A: not applicable
- 18 For further details see the review protocol in appendix A.

#### 19 Methods and process

- 20 This evidence review was developed using the methods and process described in
- 21 Developing NICE guidelines: the manual. Methods specific to this review question are
- 22 described in the review protocol in appendix A and the methods document (supplementary
- 23 document 1).
- 24 Due to the absence of minimally important differences for this review, which are not
- 25 appropriate for non-comparative data, imprecision was judged based on optimal information

- 1 size criteria. Evidence was considered seriously imprecise if there were less than 300
- 2 events, based on the rule-of-thumb specified in version 3.2 of the GRADE handbook
- 3 (Schünemann 2009), and very seriously imprecise if there were less than 150 events. The
- 4 threshold for very serious imprecision was a pragmatic decision, in the absence of a rule-of-
- 5 thumb being available, based on the fact that this is half the number required for serious
- 6 imprecision, which would be consistent with the approach suggested for continuous
- 7 outcomes.
- 8 Declarations of interest were recorded according to NICE's conflicts of interest policy.

#### 9 Case series evidence

#### 10 Included studies

- 11 Forty studies were included for this review. These included 7 prospective case series
- 12 (Cobellis 2012, Cohen 2016, Hayashi 1994, Hayashi 1998, Ikechebelu 2018, Seyam 2016,
- 13 Sowa 1993), and 30 retrospective case series (Al-Jaroudi 2005, Al-Omari 2014, Anil 2011,
- 14 Badawy 2019, Bhargava 2005, Capitano 1991, Chung 2012, Das 2007, Dwivedi 2005,
- 15 Fataftah 2022, Ferraiolo 1995, Gazzera 1998, Gleicher 1993, Hou 2014, Kelekis 1992,
- 16 Kumpe 1990, Lang 1990, Lang 2000, Maikis 2000, Mallinarini 2010, Maubon 1992,
- 17 Nakamura 1996, Osada 2000, Papaioannou 2002, Pyra 2020, Sato 1993, Schill 1999,
- 18 Tanaka 2011a, Thurmond 1990, Woolcott 1995). Two studies (Huang 2019, Huang 2022)
- 19 compared different anti-adhesion agents that are not relevant to this review and do not reflect
- 20 standard NHS practice, and for these studies only the control (usual care) arm was
- 21 extracted. One RCT (Rahimunnisa 2009) was also included that compared different methods
- 22 of guidance (ultrasound versus tactile) but this comparison was not of interest to this review
- 23 and the arms were combined and the study treated as a prospective case series.
- 24 The included studies are summarised in Table 2.
- 25 Thirty-one studies used a tubal catheterisation procedure to treat the proximal tubal
- 26 obstruction, 26 of these studies with fluoroscopic guidance (Al-Omari 2014, Anil 2011,
- 27 Badawy 2019, Bhargava 2005, Capitano 1991, Cobellis 2012, Dwivedi 2005, Ferraiolo 1995,
- 28 Gleicher 1993, Hayashi 1998, Huang 2019, Huang 2022, Kelekis 1992, Kumpe 1990, Lang
- 29 1990, Lang 2000, Mallinarini 2010, Maubon 1992, Nakamura 1996, Osada 2000,
- 30 Papaioannou 2002, Pyra 2020, Sato 1993, Sowa 1993, Thurmond 1990, Woolcott 1995), 1
- 31 of these studies with radioscopic guidance (Gazzera 1998), 1 of these studies with video
- 32 guidance (Tanaka 2011a), and 3 studies did not report the method of guidance for tubal
- 33 catheterisation (Al-Jaroudi 2005, Fataftah 2022, Hayashi 1994). Nine studies used a tubal
- 34 cannulation procedure to treat the proximal tubal obstruction, 5 of these studies with
- 35 laparoscopic quidance (Chung 2012, Hou 2014, Ikechebelu 2018, Maikis 2000, Schill 1999),
- 36 1 of these studies with ultrasound guidance (Cohen 2016), 2 of these studies with ultrasound
- 37 or laparoscopic/tactile guidance (Rahimunnisa 2009, Seyman 2016), and 1 study did not
- 38 report the method of guidance for tubal cannulation (Das 2007).
- 39 The mean age of participants in all studies (where mean age was reported) was below 35
- 40 years, with the exception of 1 study where the mean age was 35.7 years (Ikechebelu 2018).
- 41 Mean age (or median) was not reported in 9 studies (Badawy 2019, Cohen 2016, Fataftah
- 42 2022, Ferraiolo 1995, Hayashi 1994, Kelekis 1992, Maikis 2000, Rahimunnisa 2009, Seyman
- 43 2016).
- 44 Eight studies included only those with bilateral proximal tubal obstruction (Al-Jaroudi 2005.
- 45 Gleicher 1993, Hayashi 1994, Kumpe 1990, Osada 2000, Pyra 2020, Rahimunnisa 2009,
- 46 Seyam 2016), 1 study included only those with unilateral proximal tubal obstruction (Fataftah
- 47 2022), and 30 studies included those with either unilateral or bilateral proximal tubal
- 48 obstruction (Al-Omari 2014, Anil 2011, Badawy 2019, Bhargava 2005, Capitano 1991, Chung
- 49 2012, Cobellis 2012, Cohen 2016, Das 2007, Dwivedi 2005, Ferraiolo 1995, Gazzera 1998,

- 1 Hayashi 1998, Hou 2014, Huang 2019, Huang 2022, Ikechebelu 2018, Kelekis 1992, Lang
- 2 1990, Lang 2000, Mallarini 2010, Maubon 1992, Nakamura 1996, Papaioannou 2002, Sato
- 3 1993, Schill 1999, Sowa 1993, Tanaka 2011a, Thurmond 1990, Woolcott 1995) although in 3
- 4 of these studies results were reported separately for those with unilateral and bilateral
- 5 obstruction (Chung 2012, Cobellis 2012, Hou 2014). In 1 study (Maikis 2000) it is unclear if
- 6 the proximal tubal obstructions were unilateral, bilateral or a combination.
- 7 See the literature search strategy in appendix B and study selection flow chart in appendix C.

#### 8 Excluded studies

- 9 Studies not included in this review are listed, and reasons for their exclusion are provided in
- 10 appendix J.

#### 11 Summary of included studies

12 Summaries of the studies that were included in this review are presented in Table 2.

#### 13 Table 2: Summary of included studies

|  | illiary of illicidued  |   |  | _  |
|--|--|---|--|--|
| Study  | Population   | Intervention  | Outcomes   | Comments   |
| Al-Jaroudi<br>2005<br>Retrospective<br>case series<br>Canada | N with proximal tubal obstruction=75  Age in years, mean (SD): 33.2 (5)  Duration of subfertility in years, mean (SD): 2.9 (2.2)  Percentage with bilateral obstruction: 100  Percentage with unilateral obstruction: 0  Percentage with primary/secondar y infertility: 33/67 | Evaluation of proximal tubal obstruction: Hysterosalpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: NR             | Clinical pregnancies (spontaneous conception; intrauterine) Ectopic pregnancies Miscarriages Tubal perforations  | Follow-up (months): 30  N who underwent tubal catheterisation or cannulation: 75  N lost to follow-up: 3  Time from procedure to event in those with event in months, mean: NR (median 16.2) |
| Al-Omari<br>2014<br>Retrospective<br>case series<br>Jordan   | N with proximal tubal obstruction= 61  Age in years, mean (SD): 34 (NR; range 20-45)  Duration of subfertility in years, mean (SD):  | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> </ul> | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 61  N lost to follow-up: 0   |

| Study   | Population  | Intervention  | Outcomes   | Comments   |
|---|---|---|--|--|
| Judy  | 4 (NR; range 2-14)  Percentage with bilateral obstruction: 64  Percentage with unilateral obstruction: 36  Percentage with primary/secondar y infertility: 41/59  | Intervention  | Cutcomes   | Time from procedure to event in those with event in months, mean:  |
| Anil 2011 Retrospective case series Singapore | N with proximal tubal obstruction= 96  Age in years, mean (SD): 33.5 (NR; range 21.7-41.9)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 46  Percentage with unilateral obstruction: 54  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): Mean 12 (range 4-48)  N who underwent tubal catheterisation or cannulation: 78  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR |
| Badawy 2019 Retrospective case series US      | N with proximal tubal obstruction= 37  Age in years, mean (SD): NR (NR; range 28-51)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 39   | Evaluation of proximal tubal obstruction: Hysterosalpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic                            | Clinical pregnancies (spontaneous conception; intrauterine)  | Follow-up (months): NR  N who underwent tubal catheterisation or cannulation: 36  N lost to follow-up: 1  Time from procedure to event in those with event in                                    |

| Study   | Population   | Intervention  | Outcomes   | Comments  |
|---|--|---|--|---|
|   | Percentage with unilateral obstruction: 61  Percentage with primary/secondar y infertility: NR   |   |  | months, mean:<br>NR   |
| Bhargava<br>2005<br>Retrospective<br>case series<br>India | N with proximal tubal obstruction= 21  Age in years, mean (SD): 29.2 (NR; range 23-40)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 43  Percentage with unilateral obstruction: 57  Percentage with primary/secondar y infertility: 71/29   | Evaluation of proximal tubal obstruction: NR  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic   | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> </ul>   | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 21  N lost to follow-up: NR  Time from procedure to event in those with event in months, mean: 5  |
| Capitano 1991  Retrospective case series  Italy           | N with proximal tubal obstruction= 108  Age in years, mean (SD): 32 (NR; range 24-41)  Duration of subfertility in years, mean (SD): 5.7 (NR)  Percentage with bilateral obstruction: 45  Percentage with unilateral obstruction: 55  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 108  N lost to follow-up: 14  Time from procedure to event in those with event in months, mean: 3 |

| Study                                       | Population  | Intervention  | Outcomes   | Comments   |
|---|---|---|--|--|
| Chung 2012 Retrospective case series China  | N with proximal tubal obstruction= 70  Age in years, mean (SD): 33.8 (3.7)  Duration of subfertility in years, mean (SD): 4.5 (2.8)  Percentage with bilateral obstruction: 56  Percentage with unilateral obstruction: 44  Percentage with primary/secondar y infertility: 54/46 | Evaluation of proximal tubal obstruction: Hysteroscopy  Treatment of proximal tubal obstruction: Tubal cannulation  Method of guidance: Laparoscopic  | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): Mean 35.3 (SD=17)  N who underwent tubal catheterisation or cannulation: 70  N lost to follow-up: 17  Time from procedure to event in those with event in months, mean: NR |
| Cobellis 2012 Prospective case series Italy | N with proximal tubal obstruction= 33  Age in years, mean (SD): 27 (NR; range 23-38)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 36  Percentage with unilateral obstruction: 64  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Tubal perforations</li> </ul>   | Follow-up (months): 6  N who underwent tubal catheterisation or cannulation: 33  N lost to follow-up: 1  Time from procedure to event in those with event in months, mean: NR                  |
| Cohen 2016 Prospective case series Israel   | N with proximal<br>tubal obstruction=<br>27  Age in years,<br>mean (SD): NR   | Evaluation of proximal tubal obstruction: Hysteroscopy  Treatment of proximal tubal obstruction: Tubal cannulation  | <ul> <li>Live births<br/>(spontaneous<br/>conception)</li> <li>Clinical<br/>pregnancies<br/>(spontaneous</li> </ul>  | Follow-up<br>(months): NR<br>N who<br>underwent tubal<br>catheterisation   |

| Study  | Population  | Intervention  | Outcomes   | Comments  |
|--|---|---|--|---|
|  | Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 67  Percentage with unilateral obstruction: 33  Percentage with primary/secondar y infertility: 33/67  | Method of guidance:<br>Ultrasound   | conception;<br>intrauterine)  • Ectopic<br>pregnancies  • Miscarriages  • Tubal<br>perforations  | or cannulation: 27  N lost to follow- up: 1  Time from procedure to event in those with event in months, mean: NR (median 5)  |
| Das 2007  Retrospective case series  UK      | N with proximal tubal obstruction= 53  Age in years, mean (SD): 28 (NR; range 20-46)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 85  Percentage with unilateral obstruction: 15  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysteroscopy  Treatment of proximal tubal obstruction: Tubal cannulation  Method of guidance: NR  | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): NR  N who underwent tubal catheterisation or cannulation: 53  N lost to follow-up: 17  Time from procedure to event in those with event in months, mean: NR |
| Dwivedi 2005 Retrospective case series India | N with proximal tubal obstruction= 204  Age in years, mean (SD): 32 (NR; range 24-41)  Duration of subfertility in years, mean (SD): 3 (NR)  Percentage with bilateral obstruction: 72  | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> </ul>   | Follow-up (months): 6  N who underwent tubal catheterisation or cannulation: 204  N lost to follow-up: 4  Time from procedure to event in those with event in                   |

| Ctuck  | Donulation  | Intonvention  | 010.0  | Comments   |
|--|---|---|--|--|
| Study  | Population  | Intervention  | Outcomes   | Comments months, mean:   |
|  | Percentage with unilateral obstruction: 28  Percentage with primary/secondar y infertility: NR  |   |  | NR   |
| Fataftah<br>2022<br>Retrospective<br>case series<br>Jordan | N with proximal tubal obstruction= 38  Age in years, mean (SD): NR (55% <35)  Duration of subfertility in years, mean (SD): NR (68% <5)  Percentage with bilateral obstruction: 0  Percentage with unilateral obstruction: 100  Percentage with primary/secondar y infertility: 60.5/39.5 | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: NR          | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul>  | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 38  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: 4 (range 1-12) |
| Ferraiolo<br>1995<br>Retrospective<br>case series<br>Italy | N with proximal tubal obstruction= 117  Age in years, mean (SD): NR  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: NR  Percentage with unilateral obstruction: NR  | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> </ul> | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 117  N lost to follow-up: 30  Time from procedure to event in those with event in months, mean: 6.8          |

| 0.1  | 5  |   |  |  |
|--|--|---|--|--|
| Study  | Population  Deposite to a with   | Intervention  | Outcomes   | Comments   |
|  | Percentage with primary/secondar y infertility: NR   |   |  |  |
| Gazzera 1998  Retrospective case series  Italy         | N with proximal tubal obstruction= 302  Age in years, mean (SD): 32 (NR; range 20-42)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 38  Percentage with unilateral obstruction: 62  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Radioscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Tubal perforations</li> </ul>  | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 302  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR                  |
| Gleicher<br>1993<br>Retrospective<br>case series<br>US | N with proximal tubal obstruction= 147  Age in years, mean (SD): 32.6 (5.1)  Duration of subfertility in years, mean (SD): 4.2 (2.9)  Percentage with bilateral obstruction: 100  Percentage with unilateral obstruction: 0  Percentage with primary/secondar y infertility: NR    | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): Mean 26.3 (SD=7.1)  N who underwent tubal catheterisation or cannulation: 119  N lost to follow-up: 22  Time from procedure to event in those with event in months, mean: NR |
| Hayashi 1994 Prospective case series                   | N with proximal<br>tubal obstruction=<br>36  | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  | • Live births (spontaneous conception)   | Follow-up<br>(months): Mean<br>30 (range 3-48)   |

| Study                                      | Population  | Intervention  | Outcomes   | Comments   |
|--|---|---|--|--|
| Japan                                      | Age in years, mean (SD): NR (NR; range 21-42)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 100  Percentage with unilateral obstruction: 0  Percentage with primary/secondar y infertility: NR                      | Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: NR  | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> </ul>   | N who underwent tubal catheterisation or cannulation: 36  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR                         |
| Hayashi 1998 Prospective case series Japan | N with proximal tubal obstruction= 21  Age in years, mean (SD): 33.2 (5.2)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: NR  Percentage with unilateral obstruction: NR  Percentage with unilateral obstruction: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> </ul>             | Follow-up (months): NR  N who underwent tubal catheterisation or cannulation: 21  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR |
| Hou 2014  Retrospective case series  China | N with proximal tubal obstruction= 168  Age in years, mean (SD): 31.5 (3.8)  Duration of subfertility in years, mean (SD): 5.2 (3.3)  | Evaluation of proximal tubal obstruction: Hysteroscopy  Treatment of proximal tubal obstruction: Tubal cannulation  Method of guidance: Laparoscopic  | <ul> <li>Live births<br/>(spontaneous<br/>conception)</li> <li>Clinical<br/>pregnancies<br/>(spontaneous<br/>conception;<br/>intrauterine)</li> <li>Ectopic<br/>pregnancies</li> <li>Miscarriages</li> </ul> | Follow-up<br>(months): 24<br>N who<br>underwent tubal<br>catheterisation<br>or cannulation:<br>168<br>N lost to follow-<br>up: 14  |

| Study   | Population   | Intervention  | Outcomes  | Comments  |
|---|--|---|---|---|
|   | Percentage with bilateral obstruction: 64  Percentage with unilateral obstruction: 36  Percentage with primary/secondar y infertility: 31.5/68.5   |   |   | Time from procedure to event in those with event in months, mean: NR  |
| Huang 2019  Prospective case series (control arm of comparative study)  China | N with proximal tubal obstruction= 100  Age in years, mean (SD): 30.1 (5.2)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 76  Percentage with unilateral obstruction: 24  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | Clinical pregnancies (spontaneous conception; intrauterine) | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 100  N lost to follow-up: 2  Time from procedure to event in those with event in months, mean: NR     |
| Huang 2022  Prospective case series (control arm of RCT)  China               | N with proximal tubal obstruction= 70  Age in years, mean (SD): 30.1 (5.2)  Duration of subfertility in years, mean (SD): NR  Percentage with bilateral obstruction: 71  | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | Clinical pregnancies (spontaneous conception; intrauterine) | Follow-up (months): 12 & 36  N who underwent tubal catheterisation or cannulation: 70  N lost to follow-up: 4  Time from procedure to event in those with event in months, mean: NR |

| Study   | Donulation  | Intervention   | Outograpa  | Comments   |
|---|---|--|--|--|
| Judy  | Percentage with unilateral obstruction: 29  Percentage with primary/secondar y infertility: NR  | intervention   | Outcomes   | Comments   |
| Ikechebelu<br>2018<br>Prospective<br>case series<br>Nigeria | N with proximal tubal obstruction= 27  Age in years, mean (SD): 35.7 (4.6)  Duration of subfertility in years, mean (SD): 7.8 (3.7)  Percentage with bilateral obstruction: 89  Percentage with unilateral obstruction: 11  Percentage with primary/secondar y infertility: 37/63                 | Evaluation of proximal tubal obstruction: Hysteroscopy  Treatment of proximal tubal obstruction: Tubal cannulation  Method of guidance: Laparoscopic             | <ul> <li>Live births<br/>(spontaneous<br/>conception)</li> <li>Clinical<br/>pregnancies<br/>(spontaneous<br/>conception;<br/>intrauterine)</li> <li>Ectopic<br/>pregnancies</li> <li>Miscarriages</li> <li>Tubal<br/>perforations</li> </ul> | Follow-up (months): 6  N who underwent tubal catheterisation or cannulation: 27  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR  |
| Kelekis 1992 Retrospective case series Greece               | N with proximal tubal obstruction= 38  Age in years, mean (SD): NR (NR; range 25-35)  Duration of subfertility in years, mean (SD): NR (NR; range 2-7)  Percentage with bilateral obstruction: NR  Percentage with unilateral obstruction: NR  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul>                 | Follow-up (months): NR  N who underwent tubal catheterisation or cannulation: 38  N lost to follow-up: NR  Time from procedure to event in those with event in months, mean: 6 |

| Study                                    | Population  | Intervention  | Outcomes   | Comments  |
|--|---|---|--|---|
| Kumpe 1990 Retrospective case series US  | N with proximal tubal obstruction= 22  Age in years, mean (SD): 32.8 (NR; range 26-40)  Duration of subfertility in years, mean (SD): 3.3 (NR; range 1-7)  Percentage with bilateral obstruction: 100  Percentage with unilateral obstruction: 0  Percentage with primary/secondar y infertility: 23/77 | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Tubal perforations</li> </ul> | Follow-up (months): Mean 8.5 (range 1-16)  N who underwent tubal catheterisation or cannulation: 22  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR |
| Lang 1990  Retrospective case series  US | N with proximal tubal obstruction= 157  Age in years, mean (SD): 34 (NR; range 23-46)  Duration of subfertility in years, mean (SD): 4.6 (NR)  Percentage with bilateral obstruction: 88  Percentage with unilateral obstruction: 12  Percentage with primary/secondar y infertility: NR                | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Tubal perforations</li> </ul> | Follow-up (months): 30  N who underwent tubal catheterisation or cannulation: 96  N lost to follow-up: NR  Time from procedure to event in those with event in months, mean: NR                   |
| Lang 2000  Retrospective case series  US | N with proximal<br>tubal obstruction=<br>430  Age in years,<br>mean (SD): NR  | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  | <ul> <li>Live births<br/>(spontaneous<br/>conception)</li> <li>Ectopic<br/>pregnancies</li> </ul>  | Follow-up<br>(months): range<br>24-120<br>N who<br>underwent tubal<br>catheterisation   |

| Study                                  | Population   | Intervention  | Outoomas  | Comments  |
|--|--|---|---|---|
| Study                                  | Median 33.1 (NR;   | Treatment of proximal   | • Tubal   | or cannulation:   |
|  | range 21-46)   | tubal obstruction: Tubal catheterisation                        | • rubal perforations  | 234   |
|  | Duration of<br>subfertility in<br>years, mean (SD):                | Method of guidance:<br>Fluroscopic                              |   | N lost to follow-<br>up: 13                                       |
|  | NR (NR; ≥1.5)  Percentage with bilateral obstruction: NR           |   |   | Time from procedure to event in those with event in months, mean: |
|  | Percentage with unilateral obstruction: NR                         |   |   |   |
|  | Percentage with primary/secondar y infertility: 46/54              |   |   |   |
| Maikis 2000  Retrospective case series | N with proximal<br>tubal obstruction=<br>29                        | Evaluation of proximal tubal obstruction: Hysteroscopy          | <ul><li>Live births<br/>(spontaneous<br/>conception)</li><li>Clinical</li></ul>                 | Follow-up<br>(months): range<br>24-60                             |
| US                                     | Age in years,<br>mean (SD): NR<br>(NR; range 23-38)                | Treatment of proximal tubal obstruction: Tubal cannulation      | pregnancies<br>(spontaneous<br>conception;<br>intrauterine)                                     | N who underwent tubal catheterisation or cannulation:             |
|  | Duration of<br>subfertility in<br>years, mean (SD):<br>NR (NR; ≥1) | Method of guidance:<br>Laparoscopic                             | <ul><li> Ectopic pregnancies</li><li> Miscarriages</li></ul>                                    | N lost to follow-<br>up: 19                                       |
|  | Percentage with bilateral obstruction: NR                          |   |   | Time from procedure to event in those with event in               |
|  | Percentage with unilateral obstruction: NR                         |   |   | months, mean: 31.5  |
|  | Percentage with primary/secondar y infertility: NR                 |   |   |   |
| Mallarini<br>2010                      | N with proximal tubal obstruction=                                 | Evaluation of proximal tubal obstruction: Hysterosalpingography | • Live births (spontaneous conception)  | Follow-up<br>(months): 24   |
| Retrospective case series              | Age in years,<br>mean (SD): 30<br>(NR; range 23-37)                | Treatment of proximal tubal obstruction: Tubal catheterisation  | <ul> <li>Clinical<br/>pregnancies<br/>(spontaneous<br/>conception;<br/>intrauterine)</li> </ul> | N who underwent tubal catheterisation or cannulation:             |
|  | Duration of<br>subfertility in<br>years, mean (SD):                | Method of guidance:<br>Fluroscopic                              | Tubal perforations  | N lost to follow-up: 0  |

| Study   | Population  | Intervention  | Outcomes   | Comments   |
|---|---|---|--|--|
|   | 2.9 (NR; range 2-8)  Percentage with bilateral obstruction: 70  Percentage with unilateral obstruction: 30  Percentage with primary/secondar y infertility: NR  |   |  | Time from procedure to event in those with event in months, mean: NR   |
| Maubon 1992 Retrospective case series France              | N with proximal tubal obstruction= 64  Age in years, mean (SD): 33.5 (NR; range 26-42)  Duration of subfertility in years, mean (SD): 3.1 (NR; range 2-10)  Percentage with bilateral obstruction: NR  Percentage with unilateral obstruction: NR  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): 6  N who underwent tubal catheterisation or cannulation: 64  N lost to follow-up: 26  Time from procedure to event in those with event in months, mean: NR |
| Nakamura<br>1996<br>Retrospective<br>case series<br>Japan | N with proximal tubal obstruction= 30  Age in years, mean (SD): 30 (NR; range 23-42)  Duration of subfertility in years, mean (SD): 4 (NR; range 2-9)  Percentage with bilateral obstruction: 48  | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> </ul>   | Follow-up (months): NR  N who underwent tubal catheterisation or cannulation: 30  N lost to follow-up: 4  Time from procedure to event in those with event in                  |

|   | _   |   |  |   |
|---|---|---|--|---|
| Study   | Population  | Intervention  | Outcomes   | Comments  |
|   | Percentage with unilateral obstruction: 52  Percentage with primary/secondar y infertility: NR  |   |  | months, mean:<br>4.5 (range 1-14)   |
| Osada 2000 Retrospective case series Japan                | N with proximal tubal obstruction= 277  Age in years, mean (SD): NR Median 27.8 (NR; range 20-42)  Duration of subfertility in years, mean (SD): 6.5 (NR)  Percentage with bilateral obstruction: 100  Percentage with unilateral obstruction: 0                        | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Tubal perforations</li> </ul> | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 133  N lost to follow-up: 0  Time from procedure to event in those with event in months, mean: NR           |
| Papaioannou<br>2002<br>Retrospective<br>case series<br>UK | y infertility: NR N with proximal tubal obstruction= 231  Age in years, mean (SD): 32.6 (5.1)  Duration of subfertility in years, mean (SD): NR Median 3.6 (NR; range 0.4- 23.4)  Percentage with bilateral obstruction: NR  Percentage with unilateral obstruction: NR | Evaluation of proximal tubal obstruction: Selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Tubal perforations</li> </ul>                              | Follow-up (months): range 16-56  N who underwent tubal catheterisation or cannulation: 226  N lost to follow-up: 65  Time from procedure to event in those with event in months, mean: NR |

| Charles                                     | Demulation   | Intervention  | 0   | Commonto  |
|---|--|---|---|---|
| Study                                       | Population  Percentage with                                      | Intervention  | Outcomes  | Comments  |
|   | Percentage with primary/secondar y infertility: 35/54            |   |   |   |
| Pyra 2020                                   | N with proximal tubal obstruction= 248                           | Evaluation of proximal tubal obstruction: Selective             | <ul> <li>Clinical pregnancies (spontaneous</li> </ul> | Follow-up<br>(months): 12   |
| Retrospective case series                   | Age in years,  | salpingography  | conception;<br>intrauterine)                          | N who<br>underwent tubal  |
| Poland                                      | mean (SD): 34.4<br>(4.7)   | Treatment of proximal tubal obstruction: Tubal catheterisation  | Tubal perforations                                    | catheterisation or cannulation: 166                               |
|   | Duration of<br>subfertility in<br>years, mean (SD):<br>3.6 (2.2) | Method of guidance:<br>Fluroscopic                              |   | N lost to follow-<br>up: 17                                       |
|   | Percentage with bilateral obstruction: 100                       |   |   | Time from procedure to event in those with event in months, mean: |
|   | Percentage with unilateral obstruction: 0                        |   |   | 12.2 (range 2-<br>60)   |
|   | Percentage with primary/secondar y infertility: 56/44            |   |   |   |
| Rahimunnisa<br>2009                         | N with proximal tubal obstruction= 50                            | Evaluation of proximal tubal obstruction: Hysteroscopy          | <ul> <li>Clinical pregnancies (spontaneous</li> </ul> | Follow-up<br>(months): 6  |
| Prospective case series (RCT arms combined) | Age in years,<br>mean (SD): NR                                   | Treatment of proximal tubal obstruction: Tubal cannulation      | conception;<br>intrauterine) • Tubal<br>perforations  | N who underwent tubal catheterisation or cannulation:             |
| India                                       | Duration of<br>subfertility in<br>years, mean (SD):              | Method of guidance:<br>Ultrasound or tactile                    |   | N lost to follow-   |
|   | NR   |   |   | up: NR  |
|   | Percentage with bilateral obstruction: 100                       |   |   | Time from procedure to event in those with event in               |
|   | Percentage with unilateral obstruction: 0                        |   |   | months, mean:<br>NR   |
|   | Percentage with primary/secondar y infertility: NR               |   |   |   |
| Sato 1993                                   | N with proximal tubal obstruction= 52                            | Evaluation of proximal tubal obstruction: Hysterosalpingography | <ul> <li>Clinical pregnancies (spontaneous</li> </ul> | Follow-up<br>(months): NR   |
| Retrospective case series                   |  | ,                         | conception;<br>intrauterine)                          | N who underwent tubal   |

| _   |  |  |  | _   |
|---|--|--|--|---|
| Study   | Population   | Intervention   | Outcomes   | Comments  |
| Japan   | Age in years,<br>mean (SD): 33.6<br>(NR)   | Treatment of proximal tubal obstruction: Tubal catheterisation   | <ul> <li>Ectopic pregnancies</li> </ul>  | catheterisation<br>or cannulation:<br>52  |
|   | Duration of subfertility in years, mean (SD): 7.6 (NR; range 1-17)  Percentage with bilateral obstruction: 62  Percentage with unilateral obstruction: 38  Percentage with primary/secondar  | Method of guidance:<br>Fluroscopic   |  | N lost to follow-up: NR  Time from procedure to event in those with event in months, mean: NR   |
|   | y infertility: NR  |  |  |   |
| Schill 1999 Retrospective case series Germany | N with proximal tubal obstruction= 42  Age in years, mean (SD): 31 (NR; range 22-38)  Duration of subfertility in years, mean (SD): 1.6 (NR; range 1-2.9)  Percentage with bilateral obstruction: 43  Percentage with unilateral obstruction: 57  Percentage with primary/secondar | Evaluation of proximal tubal obstruction: Falloposcopy  Treatment of proximal tubal obstruction: Tubal cannulation  Method of guidance: Laparoscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> </ul> | Follow-up (months): Mean 21 (range 12-48)  N who underwent tubal catheterisation or cannulation: 42  N lost to follow-up: 4  Time from procedure to event in those with event in months, mean: NR (range 3-6) |
| Seyam 2016  Prospective case series  Egypt    | y infertility: NR N with proximal tubal obstruction= 200 Age in years, mean (SD): NR  Duration of  | Evaluation of proximal tubal obstruction: Hysteroscopy  Treatment of proximal tubal obstruction: Tubal cannulation                                   | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> </ul>                       | Follow-up (months): 12  N who underwent tubal catheterisation or cannulation: 200   |
|   | subfertility in  |  |  |   |

| Study  | Population  | Intervention  | Outcomes   | Comments   |
|--|---|---|--|--|
| Study  | years, mean (SD): NR (≥1)  Percentage with bilateral obstruction: 100  Percentage with unilateral obstruction: 0  Percentage with primary/secondar y infertility: 76/24   | Method of guidance:<br>Ultrasound or<br>laparoscopic  | Outcomes   | N lost to follow-<br>up: 0  Time from<br>procedure to<br>event in those<br>with event in<br>months, mean:<br>NR  |
| Sowa 1993  Prospective case series  Japan                | N with proximal tubal obstruction= 58  Age in years, mean (SD): 33 (NR; range 26-40)  Duration of subfertility in years, mean (SD): 7 (NR; range 2-17)  Percentage with bilateral obstruction: 59  Percentage with unilateral obstruction: 41  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): NR  N who underwent tubal catheterisation or cannulation: 58  N lost to follow-up: NR  Time from procedure to event in those with event in months, mean: 3 |
| Tanaka<br>2011a<br>Retrospective<br>case series<br>Japan | N with proximal tubal obstruction= 304  Age in years, mean (SD): 34.5 (3.5)  Duration of subfertility in years, mean (SD): NR (≥2)  Percentage with bilateral obstruction: 67   | Evaluation of proximal tubal obstruction: Falloposcopy  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Video   | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul>   | Follow-up (months): 9  N who underwent tubal catheterisation or cannulation: 304  N lost to follow-up: 56  Time from procedure to event in those with event in                 |

| Study   | Population   | Intervention  | Outcomes   | Comments   |
|---|--|---|--|--|
| Study   | Percentage with unilateral obstruction: 33  Percentage with primary/secondar y infertility: NR   | intervention  | Outcomes   | months, mean:<br>NR  |
| Thurmond<br>1990<br>Retrospective<br>case series<br>US        | N with proximal tubal obstruction= 100  Age in years, mean (SD): 32 (NR; range 19-46)  Duration of subfertility in years, mean (SD): 4 (NR)  Percentage with bilateral obstruction: NR  Percentage with unilateral obstruction: NR  Percentage with primary/secondar y infertility: NR | Evaluation of proximal tubal obstruction: Hysterosalpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic                            | <ul> <li>Live births         (spontaneous conception)</li> <li>Clinical pregnancies         (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> <li>Tubal perforations</li> </ul> | Follow-up (months): 24  N who underwent tubal catheterisation or cannulation: 100  N lost to follow-up: 3  Time from procedure to event in those with event in months, mean: 7 (range 0.5-18)    |
| Woolcott<br>1995<br>Retrospective<br>case series<br>Australia | N with proximal tubal obstruction= 66  Age in years, mean (SD): 34.7 (NR)  Duration of subfertility in years, mean (SD): 1.8 (NR; range 0.25-10)  Percentage with bilateral obstruction: 71  Percentage with unilateral obstruction: 29  | Evaluation of proximal tubal obstruction: Hysterosalpingography & selective salpingography  Treatment of proximal tubal obstruction: Tubal catheterisation  Method of guidance: Fluroscopic | <ul> <li>Clinical pregnancies (spontaneous conception; intrauterine)</li> <li>Ectopic pregnancies</li> <li>Miscarriages</li> </ul>   | Follow-up (months): Mean 17 (range 3-30)  N who underwent tubal catheterisation or cannulation: 44  N lost to follow-up: 7  Time from procedure to event in those with event in months, mean: NR |

| Study | Population   | Intervention | Outcomes | Comments |
|-------|--|--------------|----------|----------|
|       | Percentage with<br>primary/secondar<br>y infertility: NR |              |          |          |

- 1 NR: not reported; SD: standard deviation
- 2 See the full evidence tables in appendix D and the forest plots in appendix E.

#### 3 Summary of the evidence

- 4 Planned subgroup analyses by age (mean ≤35 years and >35 years) were not possible as
- 5 the mean age of participants in all studies (where mean age was reported) was below 35
- 6 years, with the exception of 1 study where the mean age was 35.7 years.
- 7 In the event of serious or very serious heterogeneity, subgroup analyses were performed (in
- 8 addition to primary analyses) for those with bilateral proximal tubal obstruction, and those
- 9 with unilateral proximal tubal obstruction. Stratified analyses were also performed based on
- 10 length of follow-up for the critical outcomes.
- 11 See appendix F for modified GRADE tables.

#### 12 Potential benefits of tubal catheterisation or cannulation

- 13 Very low quality evidence from 20 case series studies showed a live birth rate (spontaneous
- 14 conception) of 16% (95% confidence interval [CI] 12% to 20%) for those who underwent
- 15 tubal catheterisation or cannulation for the treatment of proximal tubal obstruction. However,
- 16 there was serious heterogeneity in live birth rates. Stratified analyses showed a live birth rate
- 17 of 16% (95% CI 10% to 26%) for those with bilateral obstruction, and 22% (95% CI 14% to
- 18 33%) for those with unilateral obstruction, but heterogeneity remained serious in these
- 19 stratified analyses. Analyses stratified by length of follow-up showed a live birth rate of 13%
- 20 (95% CI 6% to 25%) where spontaneous conception occurred within 6 months following the
- 21 procedure, 19% (95% CI 10% to 33%) where pregnancies occurred within 12months
- 22 following the procedure, and 17% (95% CI 12% to 22%) where pregnancies occurred at least
- 23 24 months after the procedure. Heterogeneity was serious or very serious for all follow-up
- 24 intervals.
- 25 Very low quality evidence from 39 case series studies showed a clinical pregnancy rate
- 26 (spontaneous intrauterine pregnancy) of 20% (95% CI 17% to 24%) for those who underwent
- 27 tubal catheterisation or cannulation for the treatment of proximal tubal obstruction. However,
- 28 there was very serious heterogeneity in clinical pregnancy, with rates ranging from 2% to
- 29 41%. Stratified analyses showed a clinical pregnancy rate of 19% (95% CI 12% to 28%) for
- 30 those with bilateral obstruction, and 31% (95% CI 22% to 41%) for those with unilateral
- 31 obstruction, but heterogeneity remained very serious or serious in these stratified analyses.
- 32 Analyses stratified by length of follow-up showed a clinical pregnancy rate of 21% (95% CI
- 33 15% to 28%) at 6-12 month follow-up, and 21% (95% CI 16% to 28%) at follow-up of 17-
- 34 months and longer. Heterogeneity was serious or very serious for all follow-up intervals.

#### 35 Potential harms of tubal catheterisation or cannulation

- 36 Very low quality evidence from 31 case series studies showed an ectopic pregnancy rate of
- 37 2% (95% CI 1% to 2%) following tubal catheterisation or cannulation.
- 38 Very low quality evidence from 22 case series studies showed a miscarriage rate of 4% (95%
- 39 Cl 3% to 5%) following tubal catheterisation or cannulation.
- 40 Very low quality evidence from 24 case series studies showed a tubal perforation rate of 2%
- 41 (95% CI 1% to 3%) during tubal catheterisation or cannulation.

#### 1 Economic evidence

- 2 A total of 130 studies were identified in the health economic literature search for this review
- 3 question. After duplicates were removed, 103 studies were sifted on title and abstract, of
- 4 which were excluded at this stage.

#### 5 Included studies

- 6 A systematic review of the economic literature was conducted but no economic studies were
- 7 identified which were applicable to this review question.
- 8 Also see the literature search strategy in appendix B and the economic study selection flow
- 9 chart in appendix G.

#### 10 Excluded studies

- 11 Economic studies not included in this review are listed, and reasons for their exclusion are
- 12 provided in appendix J.

#### 13 Economic model

- 14 No economic modelling was undertaken for this review because the committee agreed that
- 15 other topics were higher priorities for economic evaluation.

#### 16 Unit costs

#### 17 Table 3: Unit costs

| Resource          | Unit costs | Source  |
|-------------------|------------|---|
| Tubal cannulation | £850       | https://www.rbmojournal.com/article/S1472-6483(10)60362-8/pdf |

#### 18 The committee's discussion and interpretation of the evidence

#### 19 The outcomes that matter most

- 20 Live birth and clinical pregnancy were prioritised as critical outcomes by the committee. They
- 21 were selected as the best indicators of fertility and were specified in the core outcome set for
- 22 fertility research (Duffy 2020).
- 23 Ectopic pregnancies, miscarriage, and tubal perforations were identified as important
- 24 outcomes by the committee. Ectopic pregnancy and miscarriage were prioritised as
- 25 important outcomes as they provide meaningful information about the success of a
- 26 pregnancy and can have a significant impact on the woman's psychological and physical
- 27 health. The committee prioritised tubal perforations as an important outcome as it is
- 28 necessary when discussing and deciding on whether to undertake tubal
- 29 catheterisation/cannulation that risks are considered and weighed up against potential
- 30 benefits.

#### 31 The quality of the evidence

- 32 The quality of evidence was assessed using modified GRADE methodology. The evidence
- 33 was very low quality due to risk of bias (e.g. arising from issues with the selection of
- 34 participants into the studies, outcome measurement, and reporting of results and setting),
- 35 inconsistency (heterogeneity unexplained by subgroup analysis), and imprecision due to
- 36 small number of events.

#### 1 Benefits and harms

- 2 The committee considered the evidence for the potential benefits of fallopian tube
- 3 catheterisation for people with proximal tubal obstruction and noted that although the
- 4 evidence was non-comparative and very low quality, there was some benefit of tubal
- 5 catheterisation. For instance, for people with bilateral obstruction, who would not be able to
- 6 conceive without the procedure, a live birth rate of 16% and clinical pregnancy rate of 19%
- 7 could be considered as an appreciable potential benefit.
- 8 However, the committee noted the considerable heterogeneity associated with the live birth
- 9 and clinical pregnancy rates, which remained when analyses were stratified by bilateral or
- 10 unilateral obstruction, or by length of follow-up. The committee agreed that although tubal
- 11 catheterisation appeared to offer some benefit, the magnitude of this effect was uncertain.
- 12 The committee also discussed that in clinical practice, IVF was often offered to people with
- 13 proximal tubal obstruction, and without comparative trials comparing this procedure to
- 14 alternative treatments, it was difficult to make a strong recommendation for tubal
- 15 catheterisation.
- 16 The committee highlighted that the evidence on potential harms associated with tubal
- 17 catheterisation was more consistent, and the rate of tubal perforation was consistent with it
- 18 being a fairly safe surgical procedure. The committee reflected that the ectopic pregnancy
- 19 rate was in line with their clinical knowledge and experience given that those with complete
- 20 or partial proximal tubal obstruction have a higher risk of ectopic pregnancy than the general
- 21 population. The committee also noted that the miscarriage rate associated with tubal
- 22 catheterisation was not higher, and may be lower, than miscarriage rates associated with
- 23 other fertility treatments.
- 24 The committee discussed that for some patients tubal catheterisation may be the preferred
- 25 treatment option, particularly where there might be religious or other objections to IVF, or
- 26 where IVF might not be expected to have a significantly higher success rate relative to
- 27 spontaneous conception as in the case of those with diminished ovarian reserve.
- 28 Given the uncertainties around the potential benefits, the better evidence for a lack of harm,
- 29 and the importance of patient preference and shared decision making, the committee agreed
- 30 that fallopian tube catheterisation should be considered for those with proximal tubal
- 31 obstruction. However, this should be in the context of a full treatment discussion that includes
- 32 tubal catheterisation but also covers the anticipated relative risks and benefits of other fertility
- 33 treatments including IVF.

#### 34 Cost effectiveness and resource use

- 35 No economic evidence was identified for this review question; therefore, the committee made
- 36 a qualitative assessment on the cost effectiveness of their recommendations.
- 37 The committee noted that tubal catheterisation/cannulation for proximal tubal obstruction has
- 38 become less common in clinical practice as IVF has become more common. Nevertheless,
- 39 with some evidence of benefit they believed that it could be a cost-effective option for those
- 40 who may not want IVF. The committee reasoned that a consider recommendation could be
- 41 supported. The committee believe the recommendations are reflective of current practice and
- 42 are not anticipated to result in a significant resource impact.

#### 43 Recommendations supported by this evidence review

45 This evidence review supports recommendation 1.6.2.

46

44

#### 1 References - included studies

#### 2 Case series

#### 3 Al-Jaroudi 2005

- 4 Al-Jaroudi D, Herba MJ, Tulandi T. Reproductive performance after selective tubal
- 5 catheterization. Journal of minimally invasive gynecology. 2005 Apr 1;12(2):150-2.

#### 6 Al-Omari 2014

- 7 Al-Omari MH, Al-mnayyis A, Obeidat N, Amarin Z, Zayed F, Rousan L, Al-balas H, Alawneh
- 8 K, El-heis M, Omari Z, Hanania R. Fallopian tube recanalisation using dedicated radiographic
- 9 tubal assessment set in angiography suite. Journal of Medical Imaging and Radiation
- 10 Oncology. 2014 Aug;58(4):415-21.

#### 11 Anil 2011

- 12 Anil G, Tay KH, Loh SF, Yong TT, Ong CL, Tan BS. Fluoroscopy-guided, transcervical,
- 13 selective salpingography and fallopian tube recanalisation. Journal of Obstetrics and
- 14 Gynaecology. 2011 Nov 1;31(8):746-50.

#### 15 Badawy 2019

- 16 Badawy SZ, Singer S. Proximal tubal obstruction: pathogenesis and management. Journal of
- 17 Gynecologic Surgery. 2019 Oct 1;35(5):296-8.

#### 18 Bhargava 2005

- 19 Bhargava S, Arora P, Mohan S. Fluoroscopic guided fallopian tube recanalisation. Medical
- 20 Journal Armed Forces India. 2005 Jul 1;61(3):224-6.

#### 21 Capitano 1991

- 22 Capitanio GL, Ferraiolo A, Croce S, Gazzo R, Anserini P, de Cecco L. Transcervical
- 23 selective salpingography: a diagnostic and therapeutic approach to cases of proximal tubal
- 24 injection failure. Fertility and sterility. 1991 Jun 1;55(6):1045-50.

#### 25 **Chung 2012**

- 26 Chung JP, Haines CJ, Kong GW. Long-term reproductive outcome after hysteroscopic
- 27 proximal tubal cannulation-an outcome analysis. Australian and New Zealand Journal of
- 28 Obstetrics and Gynaecology. 2012 Oct;52(5):470-5.

#### 29 Cobellis 2012

- 30 Cobellis L, Argano F, Castaldi MA, Acone G, Mele D, Signoriello G, Colacurci N. Selective
- 31 salpingography: preliminary experience of an office operative option for proximal tubal
- 32 recanalization. European Journal of Obstetrics & Gynecology and Reproductive Biology.
- 33 2012 Jul 1;163(1):62-6.

#### 34 Cohen 2016

- 35 Cohen SB, Bouaziz J, Jakobson-Setton A, Goldenberg M, Schiff E, Orvieto R, Shulman A.
- 36 Hysteroscopically guided transvaginal ultrasound tubal catheterization—a novel office
- 37 procedure. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016
- 38 Sep 1;204:113-6.

#### 39 Das 2007

- 1 Das S, Nardo LG, Seif MW. Proximal tubal disease: the place for tubal cannulation.
- 2 Reproductive biomedicine online. 2007 Jan 1;15(4):383-8.

#### 3 Dwivedi 2005

- 4 Dwivedi M, Pal R, Jain M, Sherwani P, Nimbalkar N, Agrawal V. Efficacy of Fallopian tube
- 5 catheterization for treatment of infertility. Indian Journal of Radiology and Imaging. 2005 Oct
- 6 1;15(4).

#### 7 Fataftah 2022

- 8 Fataftah J, Tayyem R, Al Rshoud F, Al-Omari M. Spontaneous pregnancy rate after fallopian
- 9 tube recanalization for unilateral obstruction with a patent contralateral tube. Egyptian
- 10 Journal of Radiology and Nuclear Medicine. 2022 Oct 31;53(1):227.

#### 11 Ferraiolo 1995

- 12 Ferraiolo A, Ferraro F, Remorgida V, Gorlero F, Capitanio GL, de Cecco L. Unexpected
- 13 pregnancies after tubal recanalization failure with selective catheterization. Fertility and
- 14 sterility. 1995 Feb 1;63(2):299-302.

#### 15 **Gazzera 1998**

- 16 Gazzera C, Gallo T, Faissola B, Zanon E. Tubal catheterization and selective
- 17 salpingography. Rays. 1998 Oct 1;23(4):735-41.

#### 18 Gleicher 1993

- 19 Gleicher N, Confino E, Corfman R, Coulam C, DeCherney A, Haas G, Katz E, Robinson E,
- 20 Tur-Kaspa I, Vermesh M. Surgery: The multicentre transcervical balloon tuboplasty study:
- 21 conclusions and comparison to alternative technologies. Human Reproduction. 1993 Aug
- 22 1;8(8):1264-71.

#### 23 Hayashi 1994

- 24 Hayashi M, Iwasaki N, Kuramae S, Izawa Y, Murata M, Yaoi Y. Transcervical fallopian tube
- 25 recanalization under fluoroscopic guidance: The Iwasaki-Hayashi catheter. Gynecologic and
- 26 obstetric investigation. 1998 Apr 3;45(3):194-8.

#### 27 Hayashi 1998

- 28 Hayashi N, Kimoto T, Sakai T, Iwasaki T, Itoh S, Ishii Y, Murashima S, Katoh N, Yamakado
- 29 K. Fallopian tube disease: limited value of treatment with fallopian tube catheterization.
- 30 Radiology. 1994 Jan;190(1):141-3.

#### 31 Hou 2014

- 32 Hou HY, Chen YQ, Li TC, Hu CX, Chen X, Yang ZH. Outcome of laparoscopy-guided
- 33 hysteroscopic tubal catheterization for infertility due to proximal tubal obstruction. Journal of
- 34 Minimally Invasive Gynecology. 2014 Mar 1;21(2):272-8.

#### 35 Huang 2019

- 36 Huang C, Wu Q, Liang J, Wang Q, He X, Xie Y, Lu Y, Su J and Tang Y (2022) Dose-Effect
- 37 Relationship of Chitosan and Danshen Combined Injection for Fallopian Tube
- 38 Recanalization. Front. Pharmacol. 13:935117. doi: 10.3389/fphar.2022.935117

#### 39 **Huang 2022**

- 40 Huang, Chen, He, Xueping, Luo, Wenfeng et al. (2019) Combined chitosan and Dan-shen
- 41 injection for long-term tubal patency in fallopian tube recanalization for infertility. Drug
- 42 delivery and translational research 9(4): 738-747

#### 1 Ikechebelu 2018

- 2 Ikechebelu JI, Eleje GU, Bhamare P, Joe-Ikechebelu NN, Okafor CD, Akintobi AO. Fertility
- 3 outcomes following laparoscopy-assisted hysteroscopic fallopian tube cannulation: a
- 4 preliminary study. Obstetrics and gynecology international. 2018 Jun 6;2018.

#### 5 **Kelekis 1992**

- 6 Kelekis D, Papageorgiou G, Fezoulidis I, Zacharopoulos G, Kapetanakis N, Kelekis N.
- 7 Selective transcervical recanalization of fallopian tubes: a method for diagnosis and
- 8 treatment of infertility. J Interv Radiol. 1992;7:37-40.

#### 9 Kumpe 1990

- 10 Kumpe DA, Zwerdlinger SC, Rothbarth LJ, Durham JD, Albrecht BH. Proximal fallopian tube
- 11 occlusion: diagnosis and treatment with transcervical fallopian tube catheterization.
- 12 Radiology. 1990 Oct;177(1):183-7.

#### 13 Lang 1990

- 14 Lang EK, Dunaway HE. Efficacy of salpingography and transcervical recanalization in
- 15 diagnosis, categorization, and treatment of fallopian tube obstruction. Cardiovascular and
- 16 interventional radiology. 2000 Nov;23:417-22.

#### 17 Lang 2000

- 18 Lang EK, Dunaway Jr HE, Roniger WE. Selective osteal salpingography and transvaginal
- 19 catheter dilatation in the diagnosis and treatment of fallopian tube obstruction. AJR.
- 20 American journal of roentgenology. 1990 Apr;154(4):735-40.

#### 21 Maikis 2000

- 22 Maikis R, Anderson TL, Daniell JF. Hysteroscopic tubal cannulation: long-term results.
- 23 Gynaecological Endoscopy. 2000 Dec;9(6):397-400.

#### 24 Mallarini 2010

- 25 Mallarini G, Saba L. Role and application of hysterosalpingography and Fallopian tube
- 26 recanalization. Minerva Ginecologica. 2010 Dec 1;62(6):541-9.

#### 27 **Maubon 1992**

- 28 Maubon A, Rouanet JP, Cover S, Courtieu C, Mares P. Fallopian tube recanalization by
- 29 selective salpingography: an alternative to more invasive techniques? Human Reproduction.
- 30 1992 Nov 1;7(10):1425-8.

#### 31 Nakamura 1996

- 32 Nakamura K, Ishiguchi T, Maekoshi H, Ando Y, Tsuzaka M, Tamiya T, Suganuma N, Ishigaki
- 33 T. Selective fallopian tube catheterisation in female infertility: clinical results and absorbed
- 34 radiation dose. European Radiology. 1996 Aug;6:465-9.

#### 35 Osada 2000

- 36 Osada H, Fujii TK, Tsunoda I, Tsubata K, Satoh K, Palter SF. Outpatient evaluation and
- 37 treatment of tubal obstruction with selective salpingography and balloon tuboplasty. Fertility
- 38 and sterility. 2000 May 1;73(5):1032-6.

#### 39 Papaioannou 2002

- 40 Papaioannou S, Afnan M, Girling AJ, Coomarasamy A, Ola B, Olufowobi O, McHugo JM,
- 41 Hammadieh N, Sharif K. Long-term fertility prognosis following selective salpingography and

- 1 tubal catheterization in women with proximal tubal blockage. Human Reproduction. 2002 Sep
- 2 1;17(9):2325-30.

#### 3 Pyra 2020

- 4 Pyra K, Szmygin M, Dymara-Konopka W, Zych A, Sojka M, Jargiełło T, Leszczyńska-
- 5 Gorzelak B. The pregnancy rate of infertile patients with proximal tubal obstruction 12
- 6 months following selective salpingography and tubal catheterization. European Journal of
- 7 Obstetrics & Gynecology and Reproductive Biology. 2020 Nov 1;254:164-9.

#### 8 Rahimunnisa 2009

- 9 Rahimunnisa S, Tanwar R, Prasad S. Ultrasound versus tactile cannulation in the treatment
- 10 of proximal tubal obstruction. International Journal of Gynecology & Obstetrics. 2009 Sep.
- 11 1;106(3):216-7.

#### 12 Sato 1993

- 13 Sato M, Yamada R, Kimura M, Maeda H, Shioyama Y, Sonomura T, Tuji K, Nishida N, Kishi
- 14 K, Tanaka K. Transvaginal fallopian tube catheterization--diagnostic and therapeutic
- 15 usefulness. Radiation Medicine. 1993 Mar 1;11(2):49-52.

#### 16 Schill 1999

- 17 Schill T, Bauer O, Felberbaum R, Küpker W, Al-Hasani S, Diedrich K. Transcervical
- 18 Falloscopic dilatation of proximal tubal occlusion. Is there an indication?. Human
- 19 Reproduction. 1999 Sep 1;14(suppl 1):137-44.

#### 20 Seyman 2016

- 21 Seyam EM, Hassan MM, Gad MT, Mahmoud HS, Ibrahim MG. Comparison of pregnancy
- 22 outcome between ultrasound-guided tubal recanalization and office-based
- 23 microhysteroscopic ostial dilatation in patients with proximal blocked tubes. International
- 24 Journal of Fertility & Sterility. 2016 Jan;9(4):497.

#### 25 **Sowa 1993**

- 26 Sowa M, Shimamoto T, Nakano R, Sato M, Yamada R. Surgery: Diagnosis and treatment of
- 27 proximal tubal obstruction by fluoroscopic transcervical Fallopian tube catheterization.
- 28 Human reproduction. 1993 Oct 1;8(10):1711-4.

#### 29 Tanaka 2011a

- 30 Tanaka Y, Tajima H, Sakuraba S, Shimokawa R, Kamei K. Renaissance of surgical
- 31 recanalization for proximal fallopian tubal occlusion: falloposcopic tuboplasty as a promising
- 32 therapeutic option in tubal infertility. Journal of Minimally Invasive Gynecology. 2011 Sep.
- 33 1;18(5):651-9.

#### 34 Thurmond 1990

- 35 Thurmond AS, Rösch J. Nonsurgical fallopian tube recanalization for treatment of infertility.
- 36 Radiology. 1990 Feb;174(2):371-4.

#### 37 Woolcott 1995

- 38 Woolcott R, Petchpud A, O'Donnell P, Stanger J. Differential impact on pregnancy rate of
- 39 selective salpingography, tubal catheterization and wire-guide recanalization in the treatment
- 40 of proximal fallopian tube obstruction. Human reproduction. 1995 Jun 1;10(6):1423-6.

#### 1 Other

#### 2 Schünemann 2009

- 3 Schünemann H, Brożek J, Oxman A. GRADE Handbook for Grading Quality of Evidence and4 Strength of Recommendation. Version 3.2. 2009

5

# 1 Appendices

## 2 Appendix A Review protocols

- 3 Review protocol for review question: What is the likelihood of spontaneous conception when tubal
- 4 catheterisation/cannulation is used for the treatment of proximal tubal obstruction?

#### 5 Table 4: Review protocol

| ID | Field                        | Content   |
|----|------------------------------|---|
| 0. | PROSPERO registration number | CRD42023478568  |
| 1. | Review title                 | Likelihood of spontaneous conception when tubal catheterisation/cannulation is used for proximal tubal obstruction  |
| 2. | Review question              | What is the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for the treatment of proximal tubal obstruction?  |
| 3. | Objective                    | To determine the likelihood of spontaneous conception when tubal catheterisation/cannulation is used for proximal tubal obstruction   |
| 4. | Searches                     | The following databases will be searched (with no date restrictions):  Clinical searches Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Database of Systematic Reviews (CDSR) Embase MEDLINE ALL Epistemonikos  Searches will be restricted by: English language Human studies |

| ID  | Field   | Content   |
|-----|---|---|
|     |   | The guideline committee will decide whether and when to re-run the searches before final submission of the review to retrieve further studies for inclusion.  |
|     |   | The full search strategies for MEDLINE database will be published in the final review.  |
| 5.  | Condition or domain being studied                 | Surgical interventions for female factor fertility problems   |
| 6.  | Population  | Inclusion: People undergoing tubal catheterisation/cannulation for the treatment of proximal tubal obstruction  |
| 7.  | Intervention/Exposure/<br>Test                    | Tubal catheterisation/cannulation for the treatment of proximal tubal obstruction   |
| 8.  | Comparator/Reference standard/Confounding factors | N/A   |
| 9.  | Types of study to be included                     | <ul> <li>Systematic reviews of case series</li> <li>Case series or arms from comparative studies</li> <li>Exclusion:</li> <li>Case series or arms from comparative studies with a sample size of less than 20 participants will be excluded</li> </ul>  |
| 10. | Other exclusion criteria                          | <ul> <li>Language limitations: non-English language papers will be excluded (unless data can be obtained, and risk of bias assessed, from an existing systematic review)</li> <li>Conference abstracts, dissertations and unpublished data will not be included unless the data can be extracted (and risk of bias assessed) from elsewhere (for instance, from an existing systematic review)</li> </ul> |
| 11. | Context   | This guidance will fully update the following NICE guideline: Fertility problems: assessment and treatment (last updated 2017; CG156)   |
| 12. | Primary outcomes (critical outcomes)              | <ul> <li>Live birth rate (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation</li> <li>Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation</li> </ul>   |
| 13. | Secondary outcomes (important outcomes)           | <ul> <li>Ectopic pregnancy rate as proportion of those who underwent tubal catheterisation/cannulation</li> <li>Miscarriage rate as proportion of those who underwent tubal catheterisation/cannulation</li> <li>Tubal perforation rate as proportion of those who underwent tubal catheterisation/cannulation</li> </ul>   |

| ID  | Field                                  | Content  |
|-----|--|--|
| 14. | Data extraction (selection and coding) | All references identified by the searches and from other sources will be uploaded into EPPI and de-duplicated. Titles and abstracts of the retrieved citations will be screened to identify studies that potentially meet the inclusion criteria outlined in the review protocol.  Dual sifting will be performed on at least 10% of records; 90% agreement is required. Disagreements will be resolved via discussion between reviewers, and consultation with senior staff if necessary.  Full versions of the selected studies will be obtained for assessment. Studies that fail to meet the inclusion criteria once the full version has been checked will be excluded at this stage. Each study excluded after checking the full version will be listed, along with the reason for its exclusion. A standardised form will be used to extract data from studies included after full-text review. The following data will be extracted: study details (reference, country where study was carried out, type and dates), participant characteristics (including age, duration of infertility, tubal disease laterality), inclusion and exclusion criteria, details of the tubal catheterisation or cannulation method, setting and follow-up, relevant outcome data and source of funding. One reviewer will extract relevant data into a standardised form, and this will be quality assessed by a senior reviewer. |
| 15. | Risk of bias (quality) assessment      | Quality assessment of individual studies will be performed using the following checklists:  ROBIS tool for systematic reviews  JBI checklist for case series  The quality assessment will be performed by one reviewer and this will be quality assessed by a senior reviewer.   |
| 16. | Strategy for data synthesis            | Depending on the availability of the evidence, the findings will be summarised narratively or quantitatively. Where possible, meta-analyses of proportions will be conducted using the metaprop function in the R software package. Data analysis will be conducted using the generalized linear mixed model (GLMM) (Lin and Chu, 2020). The outcomes will be reported as proportions with corresponding 95% confidence intervals, as well as statistical heterogeneity data (I2, T2). Heterogeneity will be explored using planned subgroup analyses (outlined below).  The overall confidence in the findings will be evaluated using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group: http://www.gradeworkinggroup.org/  Due to the absence of minimally important differences for this review, imprecision will be judged based on optimal information size (number of events) and importance of outcomes will be assessed qualitatively during committee discussions and documented in the committee's discussion and interpretation of the evidence.   |
| 17. | Analysis of sub-groups                 | Evidence will be sub-grouped by the following:  • Age (based on the mean age reported in the study):  ○ ≤35 years  |

| ID  | Field                            | Content  |         |  |
|-----|----------------------------------|--|---------|--|
|     |                                  | <ul> <li>&gt; &gt;35 years</li> <li>Laterality of proximal tubal occlusion:         <ul> <li>Unilateral</li> <li>Bilateral</li> </ul> </li> <li>Where evidence is subgrouped the committee will consider on a case by case basis if separate recommendations should be made for distinct groups. Separate recommendations may be made where there is evidence of a differential effect of interventions in distinct groups. If there is a lack of evidence in one group, the committee will consider, based on their experience, whether it is reasonable to extrapolate and assume the interventions will have similar effects in that group compared with others.</li> </ul> |         |  |
| 18. | Type and method of               |  |         | Intervention   |
|     | review                           |  |         | Diagnostic   |
|     |                                  |  |         | Prognostic   |
|     |                                  |  |         | Qualitative  |
|     |                                  |  |         | Epidemiologic  |
|     |                                  |  |         | Service Delivery   |
|     |                                  |  |         | Other (please specify) Proportional (single-arm) meta-<br>analysis |
| 19. | Language                         | English  |         |  |
| 20. | Country                          | England  |         |  |
| 21. | Anticipated or actual start date | September 2023   |         |  |
| 22. | Anticipated completion date      | November 2024  |         |  |
| 23. | Stage of review at time          | Review stage   | Started |  |
|     | of this submission               | Preliminary searches   |         |  |
|     |                                  | Piloting of the study selection process  |         |  |

| ID  | Field                   | Content  |   |   |
|-----|-------------------------|--|---|---|
|     |                         | Formal screening of search results against eligibility criteria  |   |   |
|     |                         | Data extraction  |   |   |
|     |                         | Risk of bias (quality) assessment  |   |   |
|     |                         | Data analysis  |   |   |
| 24. | Named contact           | 5a. Named contact Guideline Development Team A  5b Named contact e-mail FertilityProblems@nice.org.uk  5e Organisational affiliation of the review Guideline Development Team A, Centre for Guideline  | olinos National Instit  | ute for Health and Care Evcellance (NICE)   |
| 25. | Review team members     | Senior Technical Analyst   | eiiries, National Iristit   | ute for Fleatiff and Gare Excellence (NIGE)   |
| 20. | Teview team members     | Technical Analyst     Technical Analyst  |   |   |
| 26. | Funding sources/sponsor | This systematic review is being completed by NIC   | CE.   |   |
| 27. | Conflicts of interest   | All guideline committee members and anyone where team and expert witnesses) must declare any post declaring and dealing with conflicts of interest. Are publicly at the start of each guideline committee reconsidered by the guideline committee Chair and a person from all or part of a meeting will be documented in the minutes of the meeting. Declaration | tential conflicts of intential conflicts of intential relevant interests, meeting. Before each a senior member of umented. Any change | erest in line with NICE's code of practice for or changes to interests, will also be declared meeting, any potential conflicts of interest will be the development team. Any decisions to exclude es to a member's declaration of interests will be |
| 28. | Collaborators           | Development of this systematic review will be over development of evidence-based recommendation Members of the guideline committee are available https://www.nice.org.uk/guidance/indevelopment/   | ns in line with section<br>e on the NICE websit   | 3 of <u>Developing NICE guidelines: the manual</u> .  |

| ID  | Field  | Content   |   |                 |
|-----|--|---|---|-----------------|
| 29. | Other registration details                               | None  |   |                 |
| 30. | Reference/URL for published protocol                     | crd.york.ac.uk/PROSPERO   | D/display_record.php?RecordID=478568                                |                 |
| 31. | Dissemination plans                                      | <ul> <li>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</li> <li>notifying registered stakeholders of publication</li> <li>publicising the guideline through NICE's newsletter and alerts</li> <li>issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.</li> </ul> |   |                 |
| 32. | Keywords   | Tubal infertility, tubal occlu  | sion, tubal surgery, natural conception, tubal catheterisation, tul | bal cannulation |
| 33. | Details of existing review of same topic by same authors | None  |   |                 |
| 34. | Current review status                                    |   | Ongoing   |                 |
|     |  |   | Completed but not published   |                 |
|     |  |   | Completed and published   |                 |
|     |  |   | Completed, published and being updated                              |                 |
|     |  |   | Discontinued  |                 |
| 35. | Additional information                                   | None  |   |                 |
| 36. | Details of final publication                             | www.nice.org.uk   | Control Deviates of Controlled Trials (CNAIII) Consoleting Indicate |                 |

<sup>1</sup> CDSR: Cochrane Database of Systematic Reviews; CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health 2 Literature; GRADE: Grading of Recommendations Assessment, Development and Evaluation; INAHTA: International Health Technology Assessment database; JBI: The 3 Joanna Briggs Institute Checklist; MEDLINE: Medical Literature Analysis and Retrieval System Online; N/A: not applicable; NICE: National Institute for Health and Care 4 Excellence; PsycINFO: Psychological Information Database; ROBIS: risk of bias in systematic reviews

### 1 Appendix B Literature search strategies

- 2 Literature search strategies for review question: What is the likelihood of
- 3 spontaneous conception when tubal catheterisation/cannulation is used for the
- 4 treatment of proximal tubal obstruction?
- 5 Database: MEDLINE ALL <1946 to December 18, 2023>
- 6 Date of last search: 19/12/2023

|    | 1 last Search. 13/12/2023   |
|----|---|
| #  | Searches  |
| 1  | infertility, female/ or Infertility/ or fertility/  |
| 2  | ((tube? or tubal*) adj4 (infertil* or subfertil* or fertil* or factor?)).tw,kf.   |
| 3  | exp Fallopian Tube Diseases/  |
| 4  | Pelvic Inflammatory Disease/  |
| 5  | Fallopian Tubes/  |
| 6  | ((fallopian or uter* or proximal) adj4 (tube? or tubal*) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf. |
| 7  | ((peritubal* or oviduct* or cornual) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf.                     |
| 8  | (hydrosalpin* or hydro-salpin* or salpingiti*).tw,kf.   |
| 9  | or/1-8  |
| 10 | Catheters/ or Catheterization/ or (catheter* or microcatheter*).tw,kf.  |
| 11 | cannula/ or (cannula* or re-canali* or recanali*).tw,kf.  |
| 12 | 10 or 11  |
| 13 | 9 and 12  |
| 14 | letter/   |
| 15 | editorial/  |
| 16 | news/   |
| 17 | exp historical article/   |
| 18 | Anecdotes as topic/   |
| 19 | comment/  |
| 20 | case reports/   |
| 21 | (letter or comment*).ti.  |
| 22 | or/14-21  |
| 23 | randomized controlled trial/ or random*.ti,ab.  |
| 24 | 22 not 23   |
| 25 | animals/ not humans/  |
| 26 | exp Animals, Laboratory/  |
| 27 | exp Animal Experimentation/   |
| 28 | exp Models, Animal/   |
| 29 | exp Rodentia/   |
| 30 | (rat or rats or rodent* or mouse or mice).ti.   |
| 31 | or/24-30  |
| 32 | 13 not 31   |
| 33 | limit 32 to english language  |
|    |   |

#### 7 Database: Embase <1974 to 2023 December 18>

8 Date of last search: 19/12/2023

| # | Searches   |
|---|--|
| 1 | fertility/ or infertility/ or female fertility/ or subfertility/ or female subfertility/ |
| 2 | ((tube? or tubal*) adj4 (infertil* or subfertil* or fertil* or factor?)).tw,kf.          |
| 3 | exp uterine tube disease/  |

| #  | Searches  |
|----|---|
| 4  | pelvic inflammatory disease/  |
| 5  | uterine tube/ or Fallopian tube/  |
| 6  | ((fallopian or uter* or proximal) adj4 (tube? or tubal*) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf. |
| 7  | ((peritubal* or oviduct* or cornual) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf.                     |
| 8  | (hydrosalpin* or hydro-salpin* or salpingiti*).tw,kf.   |
| 9  | or/1-8  |
| 10 | catheter/ or microcatheter/ or hysterosalpingogram catheter/ or intrauterine catheter/ or "gynecological and obstetric catheter"/   |
| 11 | balloon catheter/ or foley balloon catheter/ or intrauterine balloon/   |
| 12 | (catheter* or microcatheter*).tw,kf.  |
| 13 | cannula/ or cannulation/ or uterine cannula/ or uterine suction cannula/  |
| 14 | (cannula* or re-canali* or recanali*).tw,kf.  |
| 15 | or/10-14  |
| 16 | 9 and 15  |
| 17 | letter.pt. or letter/   |
| 18 | note.pt.  |
| 19 | editorial.pt.   |
| 20 | case report/ or case study/   |
| 21 | (letter or comment*).ti.  |
| 22 | or/17-21  |
| 23 | randomized controlled trial/ or random*.ti,ab.  |
| 24 | 22 not 23   |
| 25 | animal/ not human/  |
| 26 | nonhuman/   |
| 27 | exp Animal Experiment/  |
| 28 | exp Experimental Animal/  |
| 29 | animal model/   |
| 30 | exp Rodent/   |
| 31 | (rat or rats or rodent* or mouse or mice).ti.   |
| 32 | or/24-31  |
| 33 | 16 not 32   |
| 34 | limit 33 to english language  |
| 35 | (conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.  |
| 36 | 34 not 35   |

### 2 Database: Cochrane Database of Systematic Reviews, Issue 12 of 12, December 2023

### 3 Date of last search: 19/12/2023

| # | Searches  |
|---|---|
| 1 | MeSH descriptor: [Infertility, Female] this term only   |
| 2 | MeSH descriptor: [Infertility] this term only   |
| 3 | MeSH descriptor: [Fertility] this term only   |
| 4 | ((tube* or tubal*) near/4 (infertil* or subfertil* or fertil* or factor*)):ti,ab,kw   |
| 5 | MeSH descriptor: [Fallopian Tube Diseases] explode all trees  |
| 6 | MeSH descriptor: [Pelvic Inflammatory Disease] this term only   |
| 7 | MeSH descriptor: [Fallopian Tubes] this term only   |
| 8 | ((fallopian or uter* or proximal) near/4 (tube* or tubal*) near/4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)):ti,ab,kw |

| #  | Searches   |
|----|--|
| 9  | ((peritubal* or oviduct* or cornual) near/4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)):ti,ab,kw  |
| 10 | (hydrosalpin* or (hydro NEXT salpin*) or salpingiti*):ti,ab,kw   |
| 11 | {or #1-#10}  |
| 12 | MeSH descriptor: [Catheters] this term only  |
| 13 | MeSH descriptor: [Catheterization] this term only  |
| 14 | (catheter* or microcatheter*):ti,ab,kw   |
| 15 | MeSH descriptor: [Cannula] this term only  |
| 16 | (cannula* or (re NEXT canali*) or recanali*):ti,ab,kw  |
| 17 | {or #12-#16}   |
| 18 | #11 AND #17  |
| 19 | ((clinicaltrials or trialsearch* or trial-registry or trials-registry or clinicalstudies or trialsegister* or trialregister* or trial-number* or studyregister* or study-register* or controlled-trials-com or current-controlled-trial or AMCTR or ANZCTR or ChiCTR* or CRIS or CTIS or CTRI* or DRKS* or EU-CTR* or EUCTR* or EUDRACT* or ICTRP or IRCT* or JAPIC* or JMCTR* or JRCT or ISRCTN* or LBCTR* or NTR* or ReBec* or REPEC* or RPCEC* or SLCTR or TCTR* or UMIN*):so or (ctgov or ictrp)):an |
| 20 | #18 NOT #19  |
| 21 | "conference":pt  |
| 22 | #20 not #21 in Cochrane Reviews  |

- 2 Database: Cochrane Central Register of Controlled Trials
- 3 Issue 11 of 12, November 2023
- 4 Date of last search: 19/12/2023

| Date of | 1 135t Search: 19/12/2023   |
|---------|---|
| #       | Searches  |
| 1       | MeSH descriptor: [Infertility, Female] this term only   |
| 2       | MeSH descriptor: [Infertility] this term only   |
| 3       | MeSH descriptor: [Fertility] this term only   |
| 4       | ((tube* or tubal*) near/4 (infertil* or subfertil* or fertil* or factor*)):ti,ab,kw   |
| 5       | MeSH descriptor: [Fallopian Tube Diseases] explode all trees  |
| 6       | MeSH descriptor: [Pelvic Inflammatory Disease] this term only   |
| 7       | MeSH descriptor: [Fallopian Tubes] this term only   |
| 8       | ((fallopian or uter* or proximal) near/4 (tube* or tubal*) near/4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)):ti,ab,kw   |
| 9       | ((peritubal* or oviduct* or cornual) near/4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)):ti,ab,kw   |
| 10      | (hydrosalpin* or (hydro NEXT salpin*) or salpingiti*):ti,ab,kw  |
| 11      | {or #1-#10}   |
| 12      | MeSH descriptor: [Catheters] this term only   |
| 13      | MeSH descriptor: [Catheterization] this term only   |
| 14      | (catheter* or microcatheter*):ti,ab,kw  |
| 15      | MeSH descriptor: [Cannula] this term only   |
| 16      | (cannula* or (re NEXT canali*) or recanali*):ti,ab,kw   |
| 17      | {or #12-#16}  |
| 18      | #11 AND #17   |
| 19      | ((clinicaltrials or trialsearch* or trial-registry or trials-registry or clinicalstudies or trialsregister* or trialregister* or trial-number* or studyregister* or study-register* or controlled-trials-com or current-controlled-trial or AMCTR or ANZCTR or ChiCTR* or CRIS or CTIS or CTRI* or DRKS* or EU-CTR* or EUCTR* or EUDRACT* or ICTRP or IRCT* or JAPIC* or JMCTR* or JRCT or ISRCTN* or LBCTR* or NTR* or ReBec* or REPEC* or RPCEC* or SLCTR or TCTR* or UMIN*):so or (ctgov or ictrp)):an |
| 20      | #18 NOT #19   |
|         |   |

| #  | Searches              |
|----|-----------------------|
| 21 | "conference":pt       |
| 22 | #20 not #21 in Trials |

### 1 Database: Epistemonikos

### 2 Date of last search: 19/12/2023

| # | Searches  |
|---|---|
| 1 | (((tube* OR tubal*) AND (infertil* OR subfertil* OR fertil* OR factor*)) OR ((fallopian OR uter* OR proximal) AND (tube* OR tubal*) AND (patholog* OR block* OR obstruct* OR occlu* OR fibros* OR damag* OR adhesion* OR disten* OR malform* OR abnormal* OR spasm* OR polyp* OR plug* OR infect* OR scar* OR inflam* OR disease* OR lesion*)) OR ((peritubal* OR oviduct* OR cornual) AND (patholog* OR block* OR obstruct* OR occlu* OR fibros* OR damag* OR injur* OR adhesion* OR disten* OR malform* OR abnormal* OR spasm* OR polyp* OR plug* OR infect* OR scar* OR inflam* OR disease* OR lesion*)) OR hydrosalpin* OR hydro-salpin* OR (hydro AND salpin*) OR salpingiti*) |
| 2 | (catheter* OR microcatheter* OR cannula*))  |
| 3 | 1 AND 2   |

3

### 4 Health Economic Literature Search Strategies

5 Database: MEDLINE ALL <1946 to December 18, 2023>

#### 6 Date of last search: 19/12/2023

| Date of | 1 dSt Sedicii. 13/12/2023   |
|---------|---|
| #       | Searches  |
| 1       | infertility, female/ or Infertility/ or fertility/  |
| 2       | ((tube? or tubal*) adj4 (infertil* or subfertil* or fertil* or factor?)).tw,kf.   |
| 3       | exp Fallopian Tube Diseases/  |
| 4       | Pelvic Inflammatory Disease/  |
| 5       | Fallopian Tubes/  |
| 6       | ((fallopian or uter* or proximal) adj4 (tube? or tubal*) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf. |
| 7       | ((peritubal* or oviduct* or cornual) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf.                     |
| 8       | (hydrosalpin* or hydro-salpin* or salpingiti*).tw,kf.   |
| 9       | or/1-8  |
| 10      | Catheters/ or Catheterization/ or (catheter* or microcatheter*).tw,kf.  |
| 11      | cannula/ or (cannula* or re-canali* or recanali*).tw,kf.  |
| 12      | 10 or 11  |
| 13      | 9 and 12  |
| 14      | letter/   |
| 15      | editorial/  |
| 16      | news/   |
| 17      | exp historical article/   |
| 18      | Anecdotes as topic/   |
| 19      | comment/  |
| 20      | case reports/   |
| 21      | (letter or comment*).ti.  |
| 22      | or/14-21  |
| 23      | randomized controlled trial/ or random*.ti,ab.  |
| 24      | 22 not 23   |
| 25      | animals/ not humans/  |
| 26      | exp Animals, Laboratory/  |
| 27      | exp Animal Experimentation/   |
| 28      | exp Models, Animal/   |

| #  | Searches  |
|----|---|
| 29 | exp Rodentia/   |
| 30 | (rat or rats or rodent* or mouse or mice).ti.   |
| 31 | or/24-30  |
| 32 | 13 not 31   |
| 33 | limit 32 to english language  |
| 34 | Economics/  |
| 35 | Value of life/  |
| 36 | exp "Costs and Cost Analysis"/  |
| 37 | exp Economics, Hospital/  |
| 38 | exp Economics, Medical/   |
| 39 | exp Resource Allocation/  |
| 40 | Economics, Nursing/   |
| 41 | Economics, Pharmaceutical/  |
| 42 | exp "Fees and Charges"/   |
| 43 | exp Budgets/  |
| 44 | budget*.ti,ab.  |
| 45 | cost*.ti,ab.  |
| 46 | (economic* or pharmaco?economic*).ti,ab.  |
| 47 | (price* or pricing*).ti,ab.   |
| 48 | (financ* or fee or fees or expenditure* or saving*).ti,ab.                                |
| 49 | (value adj2 (money or monetary)).ti,ab.   |
| 50 | resourc* allocat*.ti,ab.  |
| 51 | (fund or funds or funding* or funded).ti,ab.  |
| 52 | (ration or rations or rationing* or rationed).ti,ab.                                      |
| 53 | ec.fs.  |
| 54 | or/34-53  |
| 55 | quality-adjusted life years/  |
| 56 | sickness impact profile/  |
| 57 | (quality adj2 (wellbeing or well being)).ti,ab.   |
| 58 | sickness impact profile.ti,ab.  |
| 59 | disability adjusted life.ti,ab.   |
| 60 | (qal* or qtime* or qwb* or daly*).ti,ab.  |
| 61 | (euroqol* or eq5d* or eq 5*).ti,ab.   |
| 62 | (qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.                             |
| 63 | (health utility* or utility score* or disutilit* or utility value*).ti,ab.                |
| 64 | (hui or hui1 or hui2 or hui3).ti,ab.  |
| 65 | (health* year* equivalent* or hye or hyes).ti,ab.   |
| 66 | discrete choice*.ti,ab.   |
| 67 | rosser.ti,ab.   |
| 68 | (willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab. |
| 69 | (sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.               |
| 70 | (sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.                    |
| 71 | (sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.               |
| 72 | (sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.                    |
| 73 | (sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.                    |
| 74 | or/55-73  |
| 75 | 33 and (54 or 74)   |

### 1 Database: Embase <1974 to 2023 December 18>

### 1 Date of last search: 19/12/2023

|    | last search: 19/12/2023   |
|----|---|
| #  | Searches  |
| 1  | fertility/ or infertility/ or female fertility/ or subfertility/ or female subfertility/  |
| 2  | ((tube? or tubal*) adj4 (infertil* or subfertil* or fertil* or factor?)).tw,kf.   |
| 3  | exp uterine tube disease/   |
| 4  | pelvic inflammatory disease/  |
| 5  | uterine tube/ or Fallopian tube/  |
| 6  | ((fallopian or uter* or proximal) adj4 (tube? or tubal*) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf. |
| 7  | ((peritubal* or oviduct* or cornual) adj4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)).tw,kf.                     |
| 8  | (hydrosalpin* or hydro-salpin* or salpingiti*).tw,kf.   |
| 9  | or/1-8  |
| 10 | catheter/ or microcatheter/ or hysterosalpingogram catheter/ or intrauterine catheter/ or "gynecological and obstetric catheter"/   |
| 11 | balloon catheter/ or foley balloon catheter/ or intrauterine balloon/   |
| 12 | (catheter* or microcatheter*).tw,kf.  |
| 13 | cannula/ or cannulation/ or uterine cannula/ or uterine suction cannula/  |
| 14 | cannula/ or (cannula* or re-canali* or recanali*).tw,kf.  |
| 15 | or/10-14  |
| 16 | 9 and 15  |
| 17 | letter.pt. or letter/   |
| 18 | note.pt.  |
| 19 | editorial.pt.   |
| 20 | case report/ or case study/   |
| 21 | (letter or comment*).ti.  |
| 22 | or/17-21  |
| 23 | randomized controlled trial/ or random*.ti,ab.  |
| 24 | 22 not 23   |
| 25 | animal/ not human/  |
| 26 | nonhuman/   |
| 27 | exp Animal Experiment/  |
| 28 | exp Experimental Animal/  |
| 29 | animal model/   |
| 30 | exp Rodent/   |
| 31 | (rat or rats or rodent* or mouse or mice).ti.   |
| 32 | or/24-31  |
| 33 | 16 not 32   |
| 34 | limit 33 to english language  |
| 35 | (conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.  |
| 36 | 34 not 35   |
| 37 | health economics/   |
| 38 | exp economic evaluation/  |
| 39 | exp health care cost/   |
| 40 | exp fee/  |
| 41 | budget/   |
| 42 | funding/  |
| 43 | resource allocation/  |
| 43 | budget*.ti,ab.  |
| 44 | cost*.ti,ab.  |
| 46 |   |
| 47 | (economic* or pharmaco?economic*).ti,ab.  |
| 48 | (price* or pricing*).ti,ab.  (financ* or fee or fees or expenditure* or saving*).ti,ab.   |
| 40 | (illiano of lee of lees of experioliture of savilly ).ti,ab.  |

| #  | Searches  |
|----|---|
| 49 | (value adj2 (money or monetary)).ti,ab.   |
| 50 | resourc* allocat*.ti,ab.  |
| 51 | (fund or funds or funding* or funded).ti,ab.  |
| 52 | (ration or rations or rationing* or rationed).ti,ab.                                      |
| 53 | or/37-52  |
| 54 | quality adjusted life year/   |
| 55 | "quality of life index"/  |
| 56 | short form 12/ or short form 20/ or short form 36/ or short form 8/                       |
| 57 | sickness impact profile/  |
| 58 | (quality adj2 (wellbeing or well being)).ti,ab.   |
| 59 | sickness impact profile.ti,ab.  |
| 60 | disability adjusted life.ti,ab.   |
| 61 | (qal* or qtime* or qwb* or daly*).ti,ab.  |
| 62 | (euroqol* or eq5d* or eq 5*).ti,ab.   |
| 63 | (qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.                             |
| 64 | (health utility* or utility score* or disutilit* or utility value*).ti,ab.                |
| 65 | (hui or hui1 or hui2 or hui3).ti,ab.  |
| 66 | (health* year* equivalent* or hye or hyes).ti,ab.   |
| 67 | discrete choice*.ti,ab.   |
| 68 | rosser.ti,ab.   |
| 69 | (willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab. |
| 70 | (sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.               |
| 71 | (sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.                    |
| 72 | (sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.               |
| 73 | (sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.                    |
| 74 | (sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.                    |
| 75 | or/54-74  |
| 76 | 36 and (53 or 75)   |

### 1 Database: INAHTA

### 2 Date of last search: 19/12/2023

| #  | Searches   |
|----|--|
| 1  | "Infertility, Female"[mh]  |
| 2  | "Infertility"[mh]  |
| 3  | "Fertility"[mh]  |
| 4  | ((tube* or tubal*) AND (infertil* or subfertil* or fertil* or factor*))  |
| 5  | "Fallopian Tube Diseases"[mhe]   |
| 6  | "Pelvic Inflammatory Disease"[mh]  |
| 7  | "Fallopian Tubes"[mh]  |
| 8  | ((fallopian or uter* or proximal) AND (tube* or tubal*) AND (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)) |
| 9  | ((peritubal* or oviduct* or cornual) AND (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*))                    |
| 10 | (hydrosalpin* or hydro-salpin* or salpingiti*)   |
| 11 | #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1  |
| 12 | "Catheters"[mh]  |
| 13 | "Catheterization"[mh]  |
| 14 | (catheter* or microcatheter*)  |
| 15 | "Cannula"[mh]  |
| 16 | (cannula* or re-canali* or recanali*)  |
| 17 | #16 OR #15 OR #14 OR #13 OR #12  |

| #  | Searches    |
|----|-------------|
| 18 | #17 AND #11 |


### 2 Database: HTA via CRD

### 3 Date of last search: 19/12/2023

| #  | Searches   |
|----|--|
| 1  | MESH DESCRIPTOR Infertility, Female  |
| 2  | MESH DESCRIPTOR Infertility  |
| 3  | MESH DESCRIPTOR Fertility  |
| 4  | ((tube* or tubal*) near4 (infertil* or subfertil* or fertil* or factor*))  |
| 5  | MESH DESCRIPTOR Fallopian Tube Diseases EXPLODE ALL TREES  |
| 6  | MESH DESCRIPTOR Pelvic Inflammatory Disease  |
| 7  | MESH DESCRIPTOR Fallopian Tubes  |
| 8  | ((fallopian or uter* or proximal) near4 (tube* or tubal*) near4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*)) |
| 9  | ((peritubal* or oviduct* or cornual) near4 (patholog* or block* or obstruct* or occlu* or fibros* or damag* or injur* or adhesion* or disten* or malform* or abnormal* or spasm* or polyp* or plug* or infect* or scar* or inflam* or disease* or lesion*))                      |
| 10 | (hydrosalpin* or hydro-salpin* or salpingiti*)   |
| 11 | #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10  |
| 12 | MESH DESCRIPTOR Catheters  |
| 13 | MESH DESCRIPTOR Catheterization  |
| 14 | (catheter* or microcatheter*)  |
| 15 | MESH DESCRIPTOR Cannula  |
| 16 | (cannula* or re-canali* or recanali*)  |
| 17 | #12 or #13 or #14 or #15 or #16  |
| 18 | #11 AND #17 IN HTA   |

### 1 Appendix C Case series evidence study selection

- 2 Study selection for: What is the likelihood of spontaneous conception when tubal
- 3 catheterisation/cannulation is used for the treatment of proximal tubal
- 4 obstruction?
- 5 Clinical search
- 6 Figure 1: Study selection flowchart



# 1 Appendix D Evidence tables

- 2 Evidence tables for: What is the likelihood of spontaneous conception when tubal
- 3 catheterisation/cannulation is used for the treatment of proximal tubal
- 4 obstruction?

5


6 Please refer to Supplement I Evidence tables for tubal catheterisation .

### Appendix E Forest plots


- 2 Forest plots for review question: What is the likelihood of spontaneous conception
- 3 when tubal catheterisation/cannulation is used for the treatment of proximal tubal
- 4 obstruction?

5


6 Figure 2: Live birth (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation



9 Figure 3: Live birth (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; bilateral subgroup



# 1 Figure 4: Live birth (spontaneous conception) as proportion of those who underwent tubal



catheterisation/cannulation; unilateral subgroup


Figure 5: Live birth (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; pregnancies within 6 months following the procedure

| Study   | Events Tot | al                   |     |     |     | F   | Proportion | 95%-0                    | CI |
|---|------------|----------------------|-----|-----|-----|-----|------------|--------------------------|----|
| lkechebelu 2018<br>Maubon 1992  | 6 2<br>5 6 | 27<br>64 —           |     | -   |     |     |            | [0.09; 0.4<br>[0.03; 0.1 | -  |
| Common effect model<br>Random effects model<br>Heterogeneity: $I^2 = 71\%$ , $\tau$ |            | 9 <b>1</b><br>= 0.06 | 0.1 | 0.2 | 0.3 | 0.4 |            | [0.07; 0.2 <sup>2</sup>  |    |


8 Figure 6: Live birth (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; pregnancies within 12 months following the procedure

| Study   | Events                   | Total                        |                 | Proportion           | 95%-CI   |
|---|--------------------------|------------------------------|-----------------|----------------------|--|
| Al-Omari 2014<br>Anil 2011<br>Capitano 1991<br>Fataftah 2022<br>Ferraiolo 1995        | 21<br>24<br>5<br>9<br>19 | 61<br>78<br>108<br>38<br>117 |                 | 0.31<br>0.05<br>0.24 | [0.23; 0.48]<br>[0.21; 0.42]<br>[0.02; 0.10]<br>[0.11; 0.40]<br>[0.10; 0.24] |
| Common effect model<br>Random effects model<br>Heterogeneity: $I^2 = 84\%$ , $\tau^2$ |                          | <b>402</b> ρ < 0.            | 0.1 0.2 0.3 0.4 |                      | [0.16; 0.24]<br>[0.10; 0.33]   |


# 1 Figure 7: Live birth (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; pregnancies ≥24-months following procedure



# 1 Figure 8: Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation




# Figure 9: Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; bilateral subgroup




5 Figure 10: Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as 6 proportion of those who underwent tubal catheterisation/cannulation; unilateral 7 subgroup

| Study   | Events Tota                | l | Proportion     | 95%-CI   |
|---|----------------------------|---|----------------|--|
| Chung 2012<br>Cobellis 2012<br>Fataftah 2022<br>Hou 2014                    | 4 3<br>9 2<br>13 3<br>21 6 | B | - 0.43<br>0.34 | [0.04; 0.30]<br>[0.22; 0.66]<br>[0.20; 0.51]<br>[0.23; 0.48] |
| Common effect model<br>Random effects mode<br>Heterogeneity: $I^2 = 50\%$ , | I                          |   |                | [0.24; 0.39]<br>[0.22; 0.41]                                 |

# Figure 11: Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; 6-12 month follow-up



5 Figure 12: Clinical pregnancy (spontaneous conception; intrauterine pregnancy) as 6 proportion of those who underwent tubal catheterisation/cannulation; ≥17 month 7 follow-up




8

# 1 Figure 13: Ectopic pregnancy as proportion of those who underwent tubal catheterisation/cannulation

| Study                                 | Events   | Total   | Proportion | 95%-CI       |
|---------------------------------------|----------|---|------------|--------------|
| Al-Jaroudi 2005                       | 0        | 75 <del>- 1</del>                                   | 0.00       | [0.00; 0.05] |
| Al-Omari 2014                         | 0        | 61 <del>- 1</del>                                   | 0.00       | [0.00; 0.06] |
| Anil 2011                             | 1        | 78 <del>- 1</del>                                   | 0.01       | [0.00; 0.07] |
| Bhargava 2005                         | 0        | 21 - 1  | 0.00       | [0.00; 0.16] |
| Capitano 1991                         | 0        | 108 <del>-                                   </del> | 0.00       | [0.00; 0.03] |
| Chung 2012                            | 1        | 70  |            | [0.00; 0.08] |
| Cobellis 2012                         | 0        | 33 - 1  |            | [0.00; 0.11] |
| Cohen 2016                            | 0        | 27  |            | [0.00; 0.13] |
| Das 2007                              | 1        | 53  |            | [0.00; 0.10] |
| Dwivedi 2005                          | 0        | 204 🕂   |            | [0.00; 0.02] |
| Ferraiolo 1995                        | 5        | 117 🗓 -   |            | [0.01; 0.10] |
| Gleicher 1993                         | 3        | 3   |            | [0.01; 0.07] |
| Hayashi 1994                          | 1        | 36  |            | [0.00; 0.15] |
| Hayashi 1998                          | 0        | 21 🕂  |            | [0.00; 0.16] |
| Hou 2014                              | 6        | 168 <del>- 1</del>                                  |            | [0.01; 0.08] |
| Ikechebelu 2018                       | 0        |   |            | [0.00; 0.13] |
| Kelekis 1992                          | 3        | -   |            | [0.02; 0.21] |
| Kumpe 1990                            | 2        |   |            | [0.01; 0.29] |
| Lang 1990                             | 0        | 96  |            | [0.00; 0.04] |
| Lang 2000                             | 1        | 234 +   |            | [0.00; 0.02] |
| Maikis 2000                           | 1        | 29 -  |            | [0.00; 0.18] |
| Maubon 1992                           | 0        | 64  |            | [0.00; 0.06] |
| Nakamura 1996                         | 2        | : —   |            | [0.01; 0.22] |
| Osada 2000                            | 2        | 1   |            | [0.00; 0.05] |
| Sato 1993                             | 2        |   |            | [0.00; 0.13] |
| Schill 1999                           | 0        | — i   |            | [0.00; 0.08] |
| Seyam 2016                            | 5        | 200   |            | [0.01; 0.06] |
| Sowa 1993                             | 2        | 3   |            | [0.00; 0.12] |
| Tanaka 2011a                          | 4        |   |            | [0.00; 0.03] |
| Thurmond 1990                         | 5        | 100 100   |            | [0.02; 0.11] |
| Woolcott 1995                         | 1        | 44  | 0.02       | [0.00; 0.12] |
| Common effect model                   |          | 2664 🌣  | 0.02       | [0.01; 0.02] |
| Random effects model                  |          | ÷   |            | [0.01; 0.02] |
| Heterogeneity: $I^2 = 0\%$ , $\tau^2$ | = 0.4484 | p = 0.95  |            |              |
| <b>3</b> ,                            |          | 0 0.05 0.1 0.15 0.2 0.25                            |            |              |
|                                       |          |   |            |              |

# 1 Figure 14: Miscarriage as proportion of those who underwent tubal catheterisation/cannulation



# 1 Figure 15: Tubal perforation as proportion of those who underwent tubal catheterisation/cannulation

| Study                                 | Events   | Total   |                                       | Proportion | 95%-CI       |
|---------------------------------------|----------|---------|---------------------------------------|------------|--------------|
| Al-Jaroudi 2005                       | 2        | 75      | -                                     | 0.03       | [0.00; 0.09] |
| Anil 2011                             | 4        | 78      | <del></del>                           |            | [0.01; 0.13] |
| Capitano 1991                         | 2        | 108     | <del></del>                           | 0.02       | [0.00; 0.07] |
| Chung 2012                            | 0        | 70      | <u> </u>                              | 0.00       | [0.00; 0.05] |
| Cobellis 2012                         | 0        | 33      | <u> </u>                              | 0.00       | [0.00; 0.11] |
| Cohen 2016                            | 0        | 27      | <u> </u>                              | 0.00       | [0.00; 0.13] |
| Das 2007                              | 1        | 53      | <del>-</del>                          |            | [0.00; 0.10] |
| Fataftah 2022                         | 0        | 38      | <u> </u>                              |            | [0.00; 0.09] |
| Gazzera 1998                          | 3        | 302     |                                       | 0.01       | [0.00; 0.03] |
| Gleicher 1993                         | 3        | 119     | <del></del>                           | 0.03       | [0.01; 0.07] |
| Ikechebelu 2018                       | 0        | 27      | <del>3</del>                          | 0.00       | [0.00; 0.13] |
| Kelekis 1992                          | 4        | 38      | <u> </u>                              |            | [0.03; 0.25] |
| Kumpe 1990                            | 2        | 22      | 3 1                                   |            | [0.01; 0.29] |
| Lang 1990                             | 0        | 96      | <u>9</u>                              | 0.00       | [0.00; 0.04] |
| Lang 2000                             | 8        | 234     | <del> </del>                          |            | [0.01; 0.07] |
| Mallarini 2010                        | 1        | 80      | •                                     |            | [0.00; 0.07] |
| Maubon 1992                           | 0        | 64      | <del>-</del> ;                        |            | [0.00; 0.06] |
| Osada 2000                            | 0        | 133     | <u>1</u>                              |            | [0.00; 0.03] |
| Papaioannou 2002                      | 5        | 226     | 3                                     |            | [0.01; 0.05] |
| Pyra 2020                             | 1        | 166     | _ ;;                                  |            | [0.00; 0.03] |
| Rahimunnisa 2009                      | 0        | 50      | <del> </del>                          |            | [0.00; 0.07] |
| Sowa 1993                             | 3        | 58      | <del>9</del> 1                        |            | [0.01; 0.14] |
| Tanaka 2011a                          | 4        | 304     | <del>-</del>                          |            | [0.00; 0.03] |
| Thurmond 1990                         | 5        | 100     | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 0.05       | [0.02; 0.11] |
| Common effect model                   |          | 2501    | ÷                                     | 0.02       | [0.01; 0.03] |
| Random effects model                  |          |         | <b>♦</b>                              | 0.02       | [0.01; 0.03] |
| Heterogeneity: $I^2 = 3\%$ , $\tau^2$ | = 0.4828 | p = 0.4 | 2                                     |            |              |
|                                       |          |         | 0.05 0.1 0.15 0.2 0.25                |            |              |

### 1 Appendix F GRADE tables

- 2 GRADE tables for review question: What is the likelihood of spontaneous conception when tubal catheterisation/cannulation
- 3 is used for the treatment of proximal tubal obstruction?

4 Table 5: Evidence profile for tubal catheterisation/cannulation

|  |                 |                              | Quality assessr      | Quality assessment No of events Effect |                              |                      | Effect              |                              |   |             |            |
|--|-----------------|------------------------------|----------------------|--|------------------------------|----------------------|---------------------|------------------------------|---|-------------|------------|
| No of studies  | Design          | Risk of bias                 | Inconsistency        | Indirectness                           | Imprecision                  | Other considerations |                     | Relative<br>(REM; 95%<br>CI) | Absolute                                      | Quality     | Importance |
| Live birth (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation |                 |                              |                      |  |                              |                      |                     |                              |   |             |            |
| 20 <sup>1</sup>  | case series     | very<br>serious <sup>2</sup> | serious <sup>3</sup> | no serious<br>indirectness             | serious <sup>4</sup>         | none                 | 268/1526<br>(17.6%) | 0.16 (0.12 to<br>0.20)       | 160 per 1000 (from<br>120 to 200 per<br>1000) | VERY<br>LOW | CRITICAL   |
| Live birth (   | spontaneous cor | nception) as p               | roportion of those   | who underwen                           | t tubal catheter             | risation/cannulatio  | on; bilateral subç  | group                        |   |             |            |
| <b>4</b> <sup>5</sup>  | case series     | serious <sup>6</sup>         | serious <sup>3</sup> | no serious<br>indirectness             | very<br>serious <sup>7</sup> | none                 | 58/301<br>(19.3%)   | 0.16 (0.10 to<br>0.26)       | 160 per 1000 (from<br>100 to 260 per<br>1000) | VERY<br>LOW | CRITICAL   |
| Live birth (   | spontaneous cor | nception) as p               | roportion of those   | e who underwen                         | t tubal catheter             | risation/cannulatio  | on; unilateral sub  | ogroup                       |   |             |            |
| 3 <sup>8</sup>   | case series     | serious <sup>6</sup>         | serious <sup>3</sup> | no serious<br>indirectness             | very<br>serious <sup>7</sup> | none                 | 30/130<br>(23.1%)   | 0.22 (0.14 to 0.33)          | 220 per 1000 (from<br>140 to 330 per<br>1000) | VERY<br>LOW | CRITICAL   |
| Live birth (   | spontaneous cor | nception) as p               | roportion of those   | e who underwen                         | t tubal catheter             | risation/cannulatio  | on; pregnancies     | within 6 month               | s following procedure                         |             |            |
| 2 <sup>9</sup>   | case series     | serious <sup>6</sup>         | serious <sup>3</sup> | no serious<br>indirectness             | very<br>serious <sup>7</sup> | none                 | 11/91<br>(12.1%)    | 0.13 (0.06 to<br>0.25)       | 130 per 1000 (from<br>60 to 250 per 1000)     | VERY<br>LOW | CRITICAL   |
| Live birth (   | spontaneous cor | nception) as p               | roportion of those   | who underwen                           | t tubal catheter             | risation/cannulatio  | on; pregnancies     | within 12 mont               | hs following the proce                        | edure       |            |

| case series      | serious <sup>6</sup>   | very serious <sup>11</sup>   | no serious indirectness   | very<br>serious <sup>7</sup>   | none   | 78/402<br>(19.4%)  | 0.19 (0.10 to<br>0.33)  | 190 per 1000 (from<br>100 to 330 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
|------------------|--|--|---|--|--|--|---|--|---|---|
| (spontaneous co  | nception) as p   | proportion of thos   | e who underwen  | nt tubal cathete   | risation/cannula   | tion; pregnancies  | ≥24-months fol  | lowing the procedure   |   |   |
| case series      | serious <sup>6</sup>   | serious <sup>3</sup>   | no serious<br>indirectness  | serious <sup>4</sup>   | none   | 153/836<br>(18.3%)   | 0.17 (0.12 to<br>0.22)  | 170 per 1000 (from<br>120 to 220 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
| regnancy (sponta | neous concep   | tion; intrauterine   | pregnancy) as p   | roportion of th  | ose who underw   | ent tubal catheter   | risation/cannula  | tion   |   |   |
| case series      | very<br>serious <sup>2</sup>   | very serious <sup>11</sup>   | no serious<br>indirectness  | no serious<br>imprecision  | none   | 559/2687<br>(20.8)   | 0.20 (0.17 to<br>0.24)  | 200 per 1000 (from<br>170 to 240 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
| regnancy (sponta | neous concep   | tion; intrauterine   | pregnancy) as p   | roportion of the   | ose who underw   | ent tubal catheter   | isation/cannula   | tion; bilateral subgro   | ap  |   |
| case series      | very<br>serious <sup>2</sup>   | very serious <sup>11</sup>   | no serious<br>indirectness  | serious <sup>4</sup>   | none   | 211/959<br>(22.0%)   | 0.19 (0.12 to<br>0.28)  | 190 per 1000 (from<br>120 to 280 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
| regnancy (sponta | neous concep   | tion; intrauterine   | pregnancy) as p   | roportion of the   | ose who underw   | ent tubal catheter   | isation/cannula   | tion; unilateral subgre  | oup   |   |
| case series      | serious <sup>6</sup>   | serious <sup>3</sup>   | no serious<br>indirectness  | very<br>serious <sup>7</sup>   | none   | 47/151<br>(31.1%)  | 0.31 (0.22 to<br>0.41)  | 310 per 1000 (from<br>220 to 410 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
| regnancy (sponta | neous concep   | tion; intrauterine   | pregnancy) as p   | roportion of the   | ose who underw   | ent tubal catheter   | risation/cannula  | tion; 6-12 month follo   | w-up  |   |
| case series      | very<br>serious <sup>2</sup>   | very serious <sup>11</sup>   | no serious indirectness   | no serious<br>imprecision  | none   | 475/2098<br>(22.6%)  | 0.21 (0.15 to<br>0.28)  | 210 per 1000 (from<br>150 to 280 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
| regnancy (sponta | neous concen   | ition: intrauterine  | pregnancy) as n   | roportion of the   | ose who underw   | ent tubal catheter   | isation/cannula   | tion: >17 month follow   | v-un  |   |
| case series      | very<br>serious <sup>2</sup>   | serious <sup>3</sup>   | no serious<br>indirectness  | serious <sup>4</sup>   | none   | 272/1155<br>(23.5%)  | 0.21 (0.16 to 0.28)   | 210 per 1000 (from<br>160 to 280 per<br>1000)  | VERY<br>LOW   | CRITICAL  |
|                  | case series  regnancy (spontal case series | (spontaneous conception) as processes and case series serious conceptions case series very serious case series very serious case series very serious case series serious case series serious case series serious case series very serious case series serious case series very very | (spontaneous conception) as proportion of thos  case series serious <sup>6</sup> serious <sup>3</sup> regnancy (spontaneous conception; intrauterine case series very serious <sup>11</sup> regnancy (spontaneous conception; intrauterine case series very serious <sup>2</sup> regnancy (spontaneous conception; intrauterine case series serious <sup>6</sup> serious <sup>3</sup> regnancy (spontaneous conception; intrauterine case series very serious <sup>11</sup> regnancy (spontaneous conception; intrauterine case series very very serious <sup>11</sup> regnancy (spontaneous conception; intrauterine case series very serious <sup>2</sup> | (spontaneous conception) as proportion of those who underwer  case series serious <sup>6</sup> serious <sup>3</sup> no serious indirectness  regnancy (spontaneous conception; intrauterine pregnancy) as present case series very serious <sup>2</sup> very serious <sup>11</sup> no serious indirectness  regnancy (spontaneous conception; intrauterine pregnancy) as present case series very serious <sup>2</sup> very serious <sup>11</sup> no serious indirectness  regnancy (spontaneous conception; intrauterine pregnancy) as present serious <sup>6</sup> serious <sup>3</sup> no serious indirectness  regnancy (spontaneous conception; intrauterine pregnancy) as present serious <sup>2</sup> very serious <sup>11</sup> no serious indirectness  regnancy (spontaneous conception; intrauterine pregnancy) as present serious <sup>2</sup> very serious <sup>11</sup> no serious indirectness  regnancy (spontaneous conception; intrauterine pregnancy) as pregnancy (spontaneous conception; intrauterine pregnancy) as presented the presented the pregnancy of the presented the present | (spontaneous conception) as proportion of those who underwent tubal catheter case series serious <sup>6</sup> serious <sup>3</sup> no serious indirectness serious <sup>4</sup> regnancy (spontaneous conception; intrauterine pregnancy) as proportion of the case series very serious <sup>2</sup> very serious <sup>11</sup> no serious indirectness imprecision  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of the case series very serious <sup>2</sup> very serious <sup>11</sup> no serious indirectness serious <sup>4</sup> regnancy (spontaneous conception; intrauterine pregnancy) as proportion of the case series serious <sup>6</sup> serious <sup>3</sup> no serious very serious <sup>7</sup> regnancy (spontaneous conception; intrauterine pregnancy) as proportion of the case series very very serious <sup>11</sup> no serious indirectness no serious indirectness indirectness serious <sup>7</sup> regnancy (spontaneous conception; intrauterine pregnancy) as proportion of the case series very serious <sup>11</sup> no serious indirectness indirectness serious indirectness indirectn | (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannular case series serious <sup>6</sup> serious <sup>3</sup> no serious serious <sup>4</sup> none  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent case series very serious <sup>11</sup> no serious indirectness indirectness indirectness no serious none  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent case series very serious <sup>11</sup> no serious indirectness serious <sup>4</sup> none  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent case series serious <sup>6</sup> serious <sup>3</sup> no serious very serious <sup>7</sup> none  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent case series very very serious <sup>11</sup> no serious indirectness indirectness indirectness indirectness no serious indirectness indirect | (19.4%)  (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; pregnancies  case series serious <sup>6</sup> serious <sup>3</sup> no serious serious <sup>4</sup> none 153/836 (18.3%)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheter  case series very serious <sup>11</sup> no serious indirectness imprecision none 559/2687 (20.8)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheter  case series very very serious <sup>11</sup> no serious serious <sup>4</sup> none 211/959 (22.0%)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheter  case series serious <sup>6</sup> serious <sup>3</sup> no serious very serious <sup>7</sup> none 47/151 (31.1%)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheter  case series very very serious <sup>11</sup> no serious indirectness indirectness indirectness none 475/2098 (22.6%)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheter  case series very very serious <sup>11</sup> no serious indirectness imprecision none 475/2098 (22.6%) | (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; pregnancies £24-months follows serious seriou | (spontaneous conception) as proportion of those who underwent tubal catheterisation/cannulation; pregnancies ≥24-months following the procedure case series serious <sup>3</sup> serious <sup>3</sup> no serious serious <sup>4</sup> none 153/836 0.17 (0.12 to 0.22) per 1000 (from 120 to 220 per 1000)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation  case series very serious <sup>11</sup> no serious indirectness no serious inprecision none 559/2687 0.20 (0.17 to 0.24) per 1000 (from 1000)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; bilateral subgrounces series very serious <sup>21</sup> no serious indirectness serious <sup>4</sup> none 211/959 0.19 (0.12 to 190 per 1000 (from 120 to 220 per 1000)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; bilateral subgrounces series serious <sup>2</sup> very serious <sup>31</sup> no serious indirectness serious <sup>4</sup> none 211/959 0.19 (0.12 to 190 per 1000 (from 120 to 220 per 1000)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; unilateral subgrounces series serious <sup>5</sup> serious <sup>3</sup> no serious indirectness very serious <sup>7</sup> none 47/151 0.31 (0.22 to 20 to 20 per 1000)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; e-12 month folio case series very very serious <sup>11</sup> no serious indirectness imprecision none 475/2098 0.21 (0.15 to 280 per 1000)  regnancy (spontaneous conception; intrauterine pregnancy) as proportion of those who underwent tubal catheterisation/cannulation; e-12 month folio case series very serious <sup>21</sup> no serious indirectness imprecision serious indirectness in none 272/1155 0.21 (0.16 to 20 per 1000 (from 150 to 280 per 1000)  1000 1000 1000 1000 1000 1000 10 | (19.4%)   0.33)   100 to 330 per   1000 |

| 31 <sup>18</sup> | case series  | very<br>serious <sup>2</sup> | no serious inconsistency    | no serious<br>indirectness | very<br>serious <sup>7</sup> | none | 35/1891<br>(1.9%) | 0.02 (0.01 to<br>0.02) | 20 per 1000 (from<br>10 to 20 per 1000) | VERY<br>LOW | IMPORTANT |
|------------------|--|------------------------------|-----------------------------|----------------------------|------------------------------|------|-------------------|------------------------|---|-------------|-----------|
| Miscarriage      | e as proportion o  | f those who u                | nderwent tubal ca           | atheterisation/ca          | nnulation                    |      |                   |                        |   |             |           |
| 2219             | case series  | very<br>serious <sup>2</sup> | no serious<br>inconsistency | no serious<br>indirectness | very<br>serious <sup>7</sup> | none | 41/999<br>(4.1%)  | 0.04 (0.03 to<br>0.05) | 40 per 1000 (from<br>30 to 50 per 1000) | VERY<br>LOW | IMPORTANT |
| Tubal perfo      | Tubal perforation as proportion of those who underwent tubal catheterisation/cannulation |                              |                             |                            |                              |      |                   |                        |   |             |           |
| 24 <sup>20</sup> | case series  | very<br>serious <sup>2</sup> | no serious inconsistency    | no serious indirectness    | very<br>serious <sup>7</sup> | none | 39/1961<br>(2.0%) | 0.02 (0.01 to 0.03)    | 20 per 1000 (from<br>10 to 30 per 1000) | VERY<br>LOW | IMPORTANT |

- 1 CI: confidence interval; JBI: The Joanna Briggs Institute Checklist; REM: random effects model
- 2 \*See corresponding forest plot
- 3 ¹Al-Omari 2014; Anil 2011; Capitano 1991; Chung 2012; Cohen 2016; Das 2007; Fataftah 2022; Ferraiolo 1995; Gleicher 1993; Hayashi 1994; Hayashi 1998; Hou 2014;
- 4 Ikechebelu 2018; Kelekis 1992; Lang 2000; Maikis 2000; Mallarini 2010; Maubon 1992; Sowa 1993; Thurmond 1990
- 5 <sup>2</sup>Very serious risk of bias in the evidence contributing to the outcome as per JBI
- 6 <sup>3</sup> Serious heterogeneity unexplained by subgroup analysis
- 7 <sup>4</sup><300-≥150 events
- 8 <sup>5</sup> Chung 2012; Gleicher 1993; Hayashi 1994; Hou 2014
- 9 <sup>6</sup>Serious risk of bias in the evidence contributing to the outcome as per JBI
- 10 7<150 events
- 11 8 Chung 2012; Fataftah 2022; Hou 2014
- 12 9 Ikechebelu 2018; Maubon 1992
- 13 <sup>10</sup> Al-Omari 2014; Anil 2011; Capitano 1991; Fataftah 2022; Ferraiolo 1995
- 14 11 Very serious heterogeneity unexplained by subgroup analysis
- 15 <sup>12</sup> Chung 2012; Gleicher 1993; Hayashi 1994; Hou 2014; Lang 2000; Maikis 2000; Mallarini 2010; Thurmond 1990
- 16 13 Al-Jaroudi 2005; Al-Omari 2014; Anil 2011; Badawy 2019; Bhargava 2005; Capitano 1991; Chung 2012; Cobellis 2012; Cohen 2016; Das 2007; Dwivedi 2005; Fataftah 2022;
- 17 Ferraiolo 1995; Gazzera 1998; Gleicher 1993; Hayashi 1994; Hayashi 1998; Hou 2014; Huang 2019; Huang 2022; Ikechebelu 2018; Kelekis 1992; Kumpe 1990; Lang 2000;
- 18 Maikis 2000; Mallarini 2010; Maubon 1992; Nakamura 1996; Osada 2000; Papaioannou 2002; Pyra 2020; Rahimunnisa 2009; Sato 1993; Schill 1999; Seyam 2016; Sowa 1993;
- 19 Tanaka 2011a; Thurmond 1990; Woolcott 1995
- 20 <sup>14</sup> Al-Jaroudi 2005; Chung 2012; Cobellis 2012; Gleicher 1993; Hayashi 1994; Hou 2014; Kumpe 1990; Osada 2000; Pyra 2020; Rahimunnisa 2009; Seyam 2016
- 21 <sup>15</sup> Chung 2012; Cobellis 2012; Fataftah 2022; Hou 2014
- 22 <sup>16</sup> Al-Omari 2014; Anil 2011; Bhargava 2005; Capitano 1991; Cobellis 2012; Dwivedi 2005; Fataftah 2022; Ferraiolo 1995; Gazzera 1998; Huang 2019; Huang 2022; Ikechebelu 23 2018; Kumpe 1990; Maubon 1992; Osada 2000; Pyra 2020; Rahimunnisa 2009; Seyam 2016; Tanaka 2011a
- 24 <sup>17</sup> Al-Jaroudi 2005; Chung 2012; Gleicher 1993; Hayashi 1994; Hou 2014; Huang 2022; Lang 2000; Maikis 2000; Mallarini 2010; Papaioannou 2002; Schill 1999; Thurmond 1990; 25 Woolcott 1995
- 26 <sup>18</sup> Al-Jaroudi 2005; Al-Omari 2014; Anil 2011; Bhargava 2005; Capitano 1991; Chung 2012; Cobellis 2012; Cohen 2016; Das 2007; Dwivedi 2005; Ferraiolo 1995; Gleicher 1993;
- 27 Hayashi 1994; Hayashi 1998; Hou 2014; Ikechebelu 2018; Kelekis 1992; Kumpe 1990; Lang 1990; Lang 2000; Maikis 2000; Maubon 1992; Nakamura 1996; Osada 2000; Sato 1992; Schill 1999; Sayam 2016; Say
- 28 1993; Schill 1999; Seyam 2016; Sowa 1993; Tanaka 2011a; Thurmond 1990; Woolcott 1995

<sup>19</sup> Al-Jaroudi 2005; Al-Omari 2014; Anil 2011; Capitano 1991; Chung 2012; Cohen 2016; Das 2007; Fataftah 2022; Ferraiolo 1995; Gleicher 1993; Hayashi 1994; Hayashi 1998; 2 Hou 2014; Ikechebelu 2018; Kelekis 1992; Maikis 2000; Maubon 1992; Schill 1999; Sowa 1993; Tanaka 2011a; Thurmond 1990; Woolcott 1995 <sup>20</sup> Al-Jaroudi 2005; Anil 2011; Capitano 1991; Chung 2012; Cobellis 2012; Cohen 2016; Das 2007; Fataftah 2022; Gazzera 1998; Gleicher 1993; Ikechebelu 2018; Kelekis 1992; Kumpe 1990; Lang 1990; Lang 2000; Mallarini 2010, Maubon 1992; Osada 2000; Papaioannou 2002; Pyra 2020, Rahimunnisa 2009; Sowa 1993; Tanaka 2011a, Thurmond 1990


### 1 Appendix G Economic evidence study selection

- 2 Study selection for: What is the likelihood of spontaneous conception when
- 3 tubal catheterisation/cannulation is used for the treatment of proximal tubal
- 4 obstruction?

6 7

8 9

5 No health economic evidence was included in this review.



# 1 Appendix H Economic evidence tables

- 2 Economic evidence tables for review question: What is the likelihood of
- 3 spontaneous conception when tubal catheterisation/cannulation is used for the
- 4 treatment of proximal tubal obstruction?
- 5 No evidence was identified which was applicable to this review question.

6

### 1 Appendix I Economic model

- 2 Economic model for review question: What is the likelihood of spontaneous
- 3 conception when tubal catheterisation/cannulation is used for the treatment of
- 4 proximal tubal obstruction?
- 5 No economic analysis was conducted for this review question.

6

# 1 Appendix J Excluded studies

- 2 Excluded studies for review question: What is the likelihood of spontaneous
- 3 conception when tubal catheterisation/cannulation is used for the treatment of
- 4 proximal tubal obstruction?
- 5 Excluded case series studies
- 6 Table 5: Excluded studies and reasons for their exclusion

| Study   | Code [Reason]  |
|---|--|
| Abdel-Aleem, H., Kamel, M.A., Hussein, M. et al. (2000) Hysteroscopic tubal cannulation for proximal tubal obstruction (PTO). Middle East Fertility Society Journal 5(2): 143-146   | - No relevant outcomes reported  |
| Al-Omari, Mamoon H, Obeidat, Nael, Elheis, Mwafiq et al. (2018) Factors Affecting Pregnancy Rate Following Fallopian Tube Recanalization in Women with Proximal Fallopian Tube Obstruction. Journal of clinical medicine 7(5)                               | - Same participants and data as an included study Further analysis of Al-Omari 2014  |
| Anonymous (2003) Transcervical fallopian tube recanalization. Clinical privilege white paper: 1-8   | - Unable to acquire paper  |
| Anonymous (2012) Transcervical fallopian tube recanalization. Clinical privilege white paper: 1-13  | - Unable to acquire paper  |
| Breckenridge, J W and Schinfeld, J S (1991) Technique for US-guided fallopian tube catheterization. Radiology 180(2): 569-70  | - Conference abstract  |
| Burke (1994) Transcervical Tubal Catheterization Utilizing Flexible Hysteroscopy is an Effective Method of Treating Cornual Obstruction: A Review Of 120 Cases. The Journal of the American Association of Gynecologic Laparoscopists 1(4part2): 5          | - Conference abstract  |
| Cohen, S.B., Shapira, M., Baron, A. et al. (2019) <u>Ultrasonography-guided hysteroscopic tubal</u> <u>catheterization of proximally occluded tubes -</u> <u>Reproductive outcomes.</u> Clinical and Experimental  Obstetrics and Gynecology 46(6): 872-875 | - Data cannot be extracted<br>Spontaneous pregnancies combined with<br>those conceived via IUI and not possible to<br>extract disaggregated data             |
| Confino, E, Tur-Kaspa, I, DeCherney, A et al. (1990) Transcervical balloon tuboplasty. A multicenter study. JAMA 264(16): 2079-82   | - Same participants and data as an included<br>study<br>Same participants and data as Gleicher<br>1993, which has larger sample size and<br>longer follow-up |
| Darcy, M D, McClennan, B L, Picus, D et al. (1991) <u>Transcervical salpingoplasty: current techniques</u> <u>and results.</u> Urologic radiology 13(1): 74-9   | - Non-systematic review  |
| Das, K; Nagel, T C; Malo, J W (1995) Hysteroscopic cannulation for proximal tubal obstruction: a change for the better?. Fertility and sterility 63(5): 1009-15   | - Data cannot be extracted  Pregnancies only reported for those with successful tubal recanalisation   |

| Study  | Code [Reason]  |
|--|--|
| De Silva, P M, Chu, J J, Gallos, I D et al. (2017) Fallopian tube catheterization in the treatment of proximal tubal obstruction: a systematic review and meta-analysis. Human reproduction (Oxford, England) 32(4): 836-852 | - Systematic review (not approrpiate to include in its entirety and checked for relevant primary studies)  |
| Dessole, S, Meloni, G B, Capobianco, G et al. (2000) A second hysterosalpingography reduces the use of selective technique for treatment of a proximal tubal obstruction. Fertility and sterility 73(5): 1037-9              | - Sample size <20<br>N=16 with proximal tubal obstruction after<br>2nd HSG   |
| Dunphy, B and Pattinson, H A (1994) Office falloposcopy; a tertiary level assessment for planning the management of infertile women. The Australian & New Zealand journal of obstetrics & gynaecology 34(2): 189-90          | - No relevant outcomes reported  |
| El-Kharoubi, Amin-Florin and Szasz, Florin (2023) Tubal Blockage Surgery: A Retrospective Cohort Study on Clinical Characteristics and Reproductive Outcomes Within Six Years. Cureus 15(6): e39879                          | - Intervention does not meet inclusion criteria<br>Intervention was either fimbriolysis or<br>salpingostomy  |
| Feng, Yun, Zhao, Han, Xu, Hongxia et al. (2019) Analysis of pregnancy outcome after anastomosis of oviduct and its influencing factors. BMC pregnancy and childbirth 19(1): 393  | - Intervention does not meet inclusion criteria<br>Laparoscopic oviduct anastomosis and tubal<br>recanalisation for sterilisation reversal   |
| Fernstrom, I (1971) A new method for studying the motility of the Fallopian tubes. Acta obstetricia et gynecologica Scandinavica 50(2): 129-33   | - Population does not meet inclusion criteria<br>Population did not have tubal obstruction   |
| Flood, J T and Grow, D R (1993) Transcervical tubal cannulation: a review. Obstetrical & gynecological survey 48(11): 768-76   | - Non-systematic review  |
| Forman, R G and Chapman, M G (1992) Therapeutic uses of transcervical catheterization of the fallopian tubes. British journal of obstetrics and gynaecology 99(3): 178-80  | - Non-systematic review  |
| Gao, T, Guo, D, Xu, M et al. (2015) A prospective study on indwelling suture in preventing re-adhesion of fallopian tube after interventional recanalization. Chinese journal of radiology (china) 49(9): 675-678            | - Study not reported in English  |
| Gleicher, N and Karande, V (1996) The diagnosis and treatment of proximal tubal disease. Human reproduction (Oxford, England) 11(9): 1825-8  | - Non-systematic review  |
| Gleicher, N, Redding, L, Parrilli, M et al. (1994) Wire guide cannulation alone is no treatment of proximal tubal occlusion. Human reproduction (Oxford, England) 9(6): 1109-11  | - Population does not meet inclusion criteria<br>All participants had already undergone<br>unsuccessful attempts at recanalization by<br>selective salpingography and are not<br>comparable to other studies |
| Golan, A and Tur-Kaspa, I (1996) The management of the infertile patient with proximal tube occlusion. Human reproduction (Oxford, England) 11(9): 1833-4  | - Non-systematic review  |
| Guerrero, R Q; Duran, A A; Ramos, R A (1972) <u>Tubal catheterization: applications of a new</u>   | - Population does not meet inclusion criteria<br>Population does not have tubal obstruction  |

| Study  | Code [Reason]  |
|--|--|
| technique. American journal of obstetrics and gynecology 114(5): 674-8   |  |
| He, Chao and Ma, Xuanpeng (2015) Distal fallopian tube recanalization using ozone treatment: a clinical study in two hundred tubal obstruction Chinese patients. International journal of clinical and experimental medicine 8(2): 2958-61 | - Population does not meet inclusion criteria<br>All participants have both distal and proximal<br>tubal obstruction and may not be<br>comparable to other studies   |
| Hepp, H; Korell, M; Strowitzki, T (1996) Proximal tubal obstructionis there a best way to treat it?. Human reproduction (Oxford, England) 11(9): 1828-31   | - Non-systematic review  |
| Hercz, P; Vine, S J; Walker, S M (1994) Experience with transcervical fallopian tube catheterization. Fertility and sterility 61(3): 551-3   | - Sample size <20  |
| Honore, G.M.; Holden, A.E.C.; Schenken, R.S. (1999) Pathophysiology and management of proximal tubal blockage. Fertility and Sterility 71(5): 785-795  | - Systematic review (not approrpiate to include in its entirety and checked for relevant primary studies)  |
| Hou, HY, Chen, YQ, Chen, X et al. (2012) [Related factors associated with pelvic adhesion and its influence on fallopian tube recanalization in infertile patients]. Zhonghua fu chan ke za zhi 47(11): 823-8                              | - Study not reported in English  |
| Houston, J G and Machan, L S (1998) Salpingitis isthmica nodosa: technical success and outcome of fluoroscopic transcervical fallopian tube recanalization. Cardiovascular and interventional radiology 21(1): 31-5                        | - Population does not meet inclusion criteria<br>Includes only a subgroup of those with<br>proximal tubal obstruction and may not be<br>comparable to other studies  |
| Hovsepian, DM, Bonn, J, Eschelman, DJ et al. (1994) Fallopian tube recanalization in an unrestricted patient population. Radiology 190(1): 137-40  | - Population does not meet inclusion criteria<br>Not restricted to those with proximal<br>obstruction and a significant proportion of<br>participants underwent another procedure<br>prior to the recanalisation |
| Jansen, R P (1993) Medicine and surgery inside the fallopian tube. The Medical journal of Australia 158(12): 799-800   | - Intervention does not meet inclusion criteria<br>Catheterisation for transfer of spermatozoa,<br>oocytes or embryos, not for treatment of<br>proximal tubal obstruction  |
| Jansen, R P and Anderson, J C (1987) Catheterisation of the fallopian tubes from the vagina. Lancet (London, England) 2(8554): 309-10  | - No relevant outcomes reported  |
| Jayakrishnan, K and Baheti, Sumeet N (2011) Laparoscopic tubal sterilization reversal and fertility outcomes. Journal of human reproductive sciences 4(3): 125-9   | - Intervention does not meet inclusion criteria<br>Tubal sterilisation reversal via recanalisation   |
| Keltz, Martin, Brown, Emma C, Frishman, Gary N et al. (2022) Fluoroscopically-Guided Hysteroscopic Tubal Cannulation: A Procedure for Proximal Tubal Obstruction. JSLS: Journal of the Society of Laparoendoscopic Surgeons 26(4)          | - Population does not meet inclusion criteria<br>All participants had already undergone<br>unsuccessful attempts at recanalization by<br>selective salpingography and are not<br>comparable to other studies     |
| Knuttinen, MG.; Jajko, R.; Scoccia, B. (2014) Fluoroscopic tubal recanalization in tubal factor  | - Non-systematic review  |

| Study   | Code [Reason]   |
|---|---|
| related infertility. Seminars in Interventional Radiology 31(3): 269-271  |   |
| Kohi, Maureen P (2021) Interventional Radiologist's Approach to Fallopian Tube Recanalization. Techniques in vascular and interventional radiology 24(1): 100736  | - Non-systematic review   |
| Lang, E K and Dunaway, H H (1996) Recanalization of obstructed fallopian tube by selective salpingography and transvaginal bougie dilatation: outcome and cost analysis. Fertility and sterility 66(2): 210-5   | - Same participants and data as an included study Recruitment dates not reported but subsequent study by same group (Lang 2000) that recruited since 1988 and data would be consistent with overlapping populations between the 2 studies |
| Lang, E.K. (1995) Transvaginal recanalization of occluded fallopian tubes. Minimally Invasive Therapy 4(3): 129-135   | - Same participants and data as an included study  All data is captured in Lang 2000  |
| Li, S C, Liu, M N, Hu, X Z et al. (1994)  Hysteroscopic tubal catheterization and hydrotubation for treatment of infertile women with tubal obstruction. Chinese medical journal 107(10): 790-3   | - Intervention does not meet inclusion criteria<br>Includes hydrotubation with drugs for 3<br>months  |
| Lisse, K and Sydow, P (1991) Fallopian tube catheterization and recanalization under ultrasonic observation: a simplified technique to evaluate tubal patency and open proximally obstructed tubes. Fertility and sterility 56(2): 198-201                                | - Sample size <20   |
| Liu, Can, Qiu, Hao, Huang, Rong et al. (2021) Therapeutic Mechanism and Clinical Observation of Traditional Chinese Medicine Combined with Interventional Recanalization for Tubal Infertility. Evidence-based complementary and alternative medicine: eCAM 2021: 2842250 | - No relevant outcomes reported   |
| Liu, WB.; Li, QX.; He, XF. (2009) Clinical application of medical ozone in the interventional therapy for infertility caused by fallopian tube adhesion. International Journal of Ozone Therapy 8(2): 198-201   | - Unable to acquire paper   |
| Markham, S (1991) Cervico-utero-tubal factors in infertility. Current opinion in obstetrics & gynecology 3(2): 191-6  | - Non-systematic review   |
| Marlow, Joshua Antranig, Picus, Daniel, Gould, Jennifer et al. (2021) Outcomes after successful fallopian tube recanalization: A single institution experience: Observational Retrospective study. Clinical imaging 76: 70-73   | - Data cannot be extracted  Only those with successful tubal recanalisation included in retrospective case series   |
| Maroulis, G B and Yeko, T R (1992) Treatment of cornual obstruction by transvaginal cannulation without hysteroscopy or fluoroscopy. Fertility and sterility 57(5): 1136-8  | - Sample size <20   |
| Matsubayashi, Hidehiko, Takaya, Yukiko, Takeuchi, Takumi et al. (2021) Falloposcopic tuboplasty: an   | - Conference abstract   |

| Study   | Code [Reason]  |
|---|--|
| easy, quick, and safe technique. Fertility and sterility 116(6): 1669-1672  |  |
| Mekaru, K, Yagi, C, Asato, K et al. (2011)  Hysteroscopic tubal catheterization under laparoscopy for proximal tubal obstruction. Archives of gynecology and obstetrics 284(6): 1573-6  | - Data cannot be extracted<br>Not possible to extract disaggregated<br>spontaneous conception pregnancy rates<br>(from pregnancies following IUI)  |
| Miyazaki, T, Kobayashi, T, Kuji, N et al. (1995) Evaluation of the radiologic findings on hysterosalpingography by selective hydrotubation with flexible hysterofiberscope. Journal of assisted reproduction and genetics 12(6): 369-74 | - Population does not meet inclusion criteria <80% of participants have proximal tubal obstruction (>20% have distal tubal obstruction)  |
| Mody, Priya; Salazar, Gloria; Kohi, Maureen P<br>(2023) Recanalization of Proximal Fallopian Tube<br>Obstruction in the Treatment of Infertility. Seminars<br>in interventional radiology 40(4): 379-383                                | - Non-systematic review  |
| Motta, EL, Nelson, J, Batzofin, J et al. (1995) Selective salpingography with an insemination catheter in the treatment of women with cornual fallopian tube obstruction. Human reproduction (Oxford, England) 10(5): 1156-9            | - Intervention does not meet inclusion criteria<br>Participants were offered different<br>conception strategies (e.g. IUI, timed<br>intercourse, gamete intra-Fallopian transfer<br>(GIFT)) based on semen analysis, female<br>age, additional infertility factors, and/or<br>failure to conceive spontaneously in first 6<br>months following tubal procedure |
| Novy, M J, Thurmond, A S, Patton, P et al. (1988) Diagnosis of cornual obstruction by transcervical fallopian tube cannulation. Fertility and sterility 50(3): 434-40   | - Sample size <20 This paper essentially reports 2 case series using different techniques (fluoroscopic catheterisation with selective salpingography; and hysteroscopic cannulation) and N in each series is <20  |
| Papaioannou, Spyros, Afnan, Masood, Girling, Alan J et al. (2003) Diagnostic and therapeutic value of selective salpingography and tubal catheterization in an unselected infertile population. Fertility and sterility 79(3): 613-7    | - Population does not meet inclusion criteria<br>Indirect population, only one third of women<br>had proximal tubal obstruction and the<br>results were not reported separately  |
| Papaioannou, Spyros, Afnan, Masoud, Girling, Alan J et al. (2003) The potential value of tubal perfusion pressures measured during selective salpingography in predicting fertility. Human reproduction (Oxford, England) 18(2): 358-63 | - Secondary analysis with no new relevant outcomes   |
| Papaioannou, Spyros, Afnan, Masoud, Girling, Alan J et al. (2002) The effect on pregnancy rates of tubal perfusion pressure reductions achieved by guide-wire tubal catheterization. Human reproduction (Oxford, England) 17(8): 2174-9 | - Secondary analysis with no new relevant outcomes   |
| Papaioannou, Spyros, Afnan, Masoud, McHugo, Josephine M et al. (2003) Modification of the coaxial technique for selective salpingography with measurement of tubal perfusion pressures. Human fertility (Cambridge, England) 6(2): 84-8 | - No relevant outcomes reported  |
| Papaioannou, Spyros; Afnan, Masoud; Sharif, Khaldoun (2004) The role of selective   | - Non-systematic review  |

| Study   | Code [Reason]  |
|---|--|
| salpingography and tubal catheterization in the management of the infertile couple. Current opinion   |  |
| in obstetrics & gynecology 16(4): 325-9   |  |
| Pennehouat, G, Risquez, F, Naouri, M et al. (1993) <u>Transcervical falloposcopy: preliminary experience.</u> Human reproduction (Oxford, England) 8(3): 445-9  | - Population does not meet inclusion criteria<br>Only 45% had proximal obstruction (55%<br>had distal obstruction)                             |
| Pinto, Anil B M, Hovsepian, David M, Wattanakumtornkul, Saranya et al. (2003) Pregnancy outcomes after fallopian tube recanalization: oil-based versus water-soluble contrast agents. Journal of vascular and interventional radiology: JVIR 14(1): 69-74       | - Data cannot be extracted Only those with successful tubal recanalisation included in retrospective case series                               |
| Ransom, MX and Garcia, AJ (1997) Surgical management of cornual-isthmic tubal obstruction. Fertility and sterility 68(5): 887-891   | - No relevant outcomes reported  |
| Rawal, N; Haddad, N; Abbott, G T (2005) Selective salpingography and fallopian tube recanalisation: experience from a district general hospital. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology 25(6): 586-8 | - Sample size <20  |
| Raymond, C.A. (1988) Balloon catheterization in infertility clinic. JAMA: the journal of the American Medical Association 259(1): 16  | - Sample size <20  |
| Rosch, J; Thurmond, A S; Uchida, B T (1988)  Diagnosis and treatment of fallopian tube obstruction with selective salpingography and catheter recanalization. Annales de radiologie 31(2): 123-6  | - No relevant outcomes reported  |
| Rosch, J, Thurmond, A S, Uchida, B T et al. (1988) Selective transcervical fallopian tube catheterization: technique update. Radiology 168(1): 1-5  | - Data cannot be extracted Paper does not report the number of participants that underwent tubal catheterisation (only the number of tubes)    |
| Sakumoto, T, Shinkawa, T, Izena, H et al. (1993) Treatment of infertility associated with endometriosis by selective tubal catheterization under hysteroscopy and laparoscopy. American journal of obstetrics and gynecology 169(3): 744-7                      | - Population does not meet inclusion criteria<br>Fertility problems associated with<br>endometriosis rather than proximal tubal<br>obstruction |
| Shen, Huawei, Huang, Shikuan, Liu, Weifeng et al. (2023) Study on the efficacy and safety of fallopian tube interventional recanalization in the treatment of tubal obstructive infertility. Panminerva medica 65(2): 254-256                                   | - Letter to the editor   |
| Shinmoto, H. (1993) Evaluation of selective salpingography and recanalization. Japanese Journal of Clinical Radiology 38(9): 1045-1049  | - Study not reported in English  |
| Stern, J J; Peters, A J; Coulam, C B (1991) Transcervical tuboplasty under ultrasonographic guidance: a pilot study. Fertility and sterility 56(2): 359-60  | - Sample size <20  |
| Sun, Niuniu, Wei, Lequn, Chen, Diansen et al. (2017) Clinical observation of fallopian tube   | - Data cannot be extracted   |

| Study  | Code [Reason]  |
|--|--|
| obstruction recanalization by ozone. Pakistan  | Exclusion criteria include those with re-  |
| journal of medical sciences 33(2): 290-294   | occlusion or abortion  |
| Surrey, Adamson, Surrey et al. (1996) Introduction of a New Coaxial Falloposcopy System. The Journal of the American Association of Gynecologic Laparoscopists 3(4supplement): 48  | - Conference abstract  |
| Tanaka, A., Tanaka, I., Yamaguchi, T. et al. (2017) Development of a new tubal recanalization method using the combination of hysteroscope and laparoscope in the treatment of obstructed fallopian tubes. Gynecology and Minimally Invasive Therapy 6(4): 1-2                                 | - Population does not meet inclusion criteria The proportion with proximal tubal obstruction is unclear  |
| Tanaka, Yudai and Tajima, Hiroto (2011) Falloposcopic tuboplasty as an option for tubal infertility: an alternative to in vitro fertilization. Fertility and sterility 95(1): 441-3  | - Data cannot be extracted Pregnancies reported following natural intercourse and IUI combined, and disaggregated data for spontaneous conceptions not available   |
| Thompson, K A, Kiltz, R J, Koci, T et al. (1994) Transcervical fallopian tube catheterization and recanalization for proximal tubal obstruction. Fertility and sterility 61(2): 243-7  | - Data cannot be extracted  Paper does not report the number of participants that underwent tubal catheterisation (only the number of tubes), and only reports pregnancy for those who had successful recanalisation |
| Thurmond, A S (1998) Interventional radiology in the treatment of infertility: fallopian tube catheterization. Radiographics: a review publication of the Radiological Society of North America, Inc 18(4): 919-22   | - Non-systematic review  |
| Thurmond, A S; Burry, K A; Novy, M J (1995) Salpingitis isthmica nodosa: results of transcervical fluoroscopic catheter recanalization. Fertility and sterility 63(4): 715-22  | - Population does not meet inclusion criteria<br>Includes only a subgroup of those with<br>proximal tubal obstruction and may not be<br>comparable to other studies  |
| Thurmond, A S, Machan, L S, Maubon, A J et al. (2000) A review of selective salpingography and fallopian tube catheterization. Radiographics: a review publication of the Radiological Society of North America, Inc 20(6): 1759-68  | - Non-systematic review  |
| Thurmond, A S, Rosch, J, Patton, P E et al. (1988) Fluoroscopic transcervical fallopian tube catheterization for diagnosis and treatment of female infertility caused by tubal obstruction. Radiographics: a review publication of the Radiological Society of North America, Inc 8(4): 621-40 | - No relevant outcomes reported  |
| Thurmond, A.S. (1991) Fallopian tube catheterization for improved diagnosis and treatment of proximal tubal obstruction. Minimally Invasive Therapy 1(1): 29-33  | - Non-systematic review  |

| Study   | Code [Reason]  |
|---|--|
| <u>Thurmond, A.S. (2000) Fallopian tube</u> <u>recanalization.</u> Seminars in Interventional Radiology 17(3): 303-308  | - Non-systematic review  |
| Vardhana, Pratibhasri A, Silberzweig, James E, Guarnaccia, Michael et al. (2009)  Hysterosalpingography with selective salpingography. The Journal of reproductive medicine 54(3): 126-32   | - No relevant outcomes reported  Pregnancy defined as biochemical test only  |
| Wadin, K, Lonnemark, M, Rasmussen, C et al. (1994) Frequency of proximal tubal obstruction in patients undergoing infertility evaluation. Acta radiologica (Stockholm, Sweden: 1987) 35(4): 357-60  | - Intervention does not meet inclusion criteria<br>Intervention was hysterosalpingography only                                     |
| Wang, Jeffrey W, Rustia, Gabriella M, Wood-Molo, Mary et al. (2020) Conception rates after fluoroscopy-guided fallopian tubal cannulation: an alternative to in vitro fertilization for patients with tubal occlusion. Therapeutic advances in reproductive health 14: 2633494120954248           | - Data cannot be extracted<br>Not possible to extract disaggregated<br>spontaneous conceptions (from conceptions<br>following IUI) |
| Woolcott, R (1996) Proximal tubal occlusion: a practical approach. Human reproduction (Oxford, England) 11(9): 1831-3   | - Non-systematic review  |
| Zagoria, R J; Regan, S W; Dyer, R B (1991) Nonsurgical fallopian tube recanalization for treatment of infertility. North Carolina medical journal 52(10): 491-3   | - Duplicate paper  |
| Zagoria, R.J.; Regan, S.W.; Dyer, R.B. (1991) Nonsurgical fallopian tube recanalization for treatment of infertility. North Carolina medical journal 52(10): 491-493  | - Non-systematic review  |
| Zhang, Y J, Fan, H M, Huang, X M et al. (1993) Microsurgical recanalization of fallopian tubes after tubosterilization and its related factors. Report of 278 cases. Chinese medical journal 106(6): 433-6  | - Intervention does not meet inclusion criteria<br>Intervention was reversal of tubosterilisation                                  |
| Zheng, RQ (2014) Clinical research on the treatment for oviduct obstruction by interventional technology under hysteroscope combining with enema with Chinese traditional medicine and physiotherapy. Dissertation for master degree of shandong university of traditional chinese medicine: 1-35 | - Study not reported in English  |

#### 1 Excluded economic studies

2 No economic evidence was identified for this review.

3

# 1 Appendix K Research recommendations – full details

- 2 Research recommendations for review question: What is the likelihood of
- 3 spontaneous conception when tubal catheterisation/cannulation is used for the
- 4 treatment of proximal tubal obstruction?
- 5 No research recommendations were made for this review question.